Clinical trial results:
A Phase I/IIa Study Assessing Single and Multiple Doses of IDX21437 in Healthy and HCV-Infected Subjects

Summary

EudraCT number	2013-004043-23
Trial protocol	BE
Global end of trial date	11 September 2015

Results information

Result version number	v1 (current)
This version publication date	26 August 2016
First version publication date	26 August 2016

Trial information

Trial identification

Sponsor protocol code	3682-001

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01974687
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme Corp.
Sponsor organisation address	2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	11 September 2015
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	11 September 2015
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

This is a multi-part study to evaluate the safety, tolerability, and pharmacokinetics (PK) of MK-3682 (IDX21437) in healthy participants and in participants infected with HCV genotype (GT)1-GT6. The effect of food on the PK of MK-3682 will be evaluated. The antiviral activity of MK-3682 will also be assessed in HCV-infected participants.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statuses and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	31 October 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 3
Country: Number of subjects enrolled	Canada: 95
Country: Number of subjects enrolled	Moldova, Republic of: 66
Country: Number of subjects enrolled	New Zealand: 14
Worldwide total number of subjects	178
EEA total number of subjects	3

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	177
From 65 to 84 years	1
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

This study enrolled healthy, adult participants (Group A), adult participants with chronic hepatitis C infection without cirrhosis (Groups B, C, D and F), and HCV-infected participants with mild hepatic impairment (Group E). Additional inclusion and exclusion criteria applied.

Period 1

Period 1 title	Overall Period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Group A - Placebo (Cohort 1a -Cohort 5a - pooled) (capsule)

Arm description:

Participants were administered a single dose of MK-3682-matching placebo as oral capsules under fasted conditions (Cohorts 1a, 2a, 3a, 5a); Participants were administered single doses of MK-3682-matching placebo as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods (Cohort 4a).

Arm type	Placebo
Investigational medicinal product name	MK-3682-matching placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MK-3682-matching placebo oral capsule x 1 day

Arm title	Group A - MK-3682 10 mg (Cohort 1a) (capsule)

Arm description:

Participants were administered a single dose of MK-3682 10 mg as oral capsules under fasted conditions.

Arm type	Experimental
Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MK-3682 10 mg oral capsule x 1 day

Arm title	Group A - MK-3682 25 mg (Cohort 2a) (capsule)

Arm description:

Participants were administered a single dose of MK-3682 25 mg as oral capsules under fasted conditions.

Arm type	Experimental

Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MK-3682 25 mg oral capsule x 1 day

Arm title	Group A - MK-3682 50 mg (Cohort 3a) (capsule)

Arm description:

Participants were administered a single dose of MK-3682 50 mg as oral capsules under fasted conditions.

Arm type	Experimental
Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MK-3682 50 mg oral capsule x 1 day

Arm title	Group A - MK-3682 150 mg (Cohort 4a) (capsule)

Arm description:

Participants were administered single doses of MK-3682 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.

Arm type	Experimental
Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MK-3682 150 mg oral capsule x 1 day

Arm title	Group A - MK-3682 300 mg (Cohort 5a) (capsule)

Arm description:

Participants were administered a single dose of MK-3682 300 mg as oral capsules under fasted conditions.

Arm type	Experimental
Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MK-3682 300 mg oral capsule x 1 day

Arm title	Group A - Placebo (Cohort 6a)

Arm description:

Participants were administered single doses of MK-3682-matching placebo as oral capsules for 7 days under fasted conditions.

Arm type	Placebo

Investigational medicinal product name	MK-3682-matching placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MK-3682-matching placebo oral capsule once daily (QD) x 7 days

Arm title	Group A - MK-3682 300 mg (Cohort 6a)

Arm description:

Participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.

Arm type	Experimental
Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MK-3682 300 mg QD x 7 days

Arm title	Group B - MK-3682 10 mg (Cohort 1b)

Arm description:

Participants were administered a single dose of MK-3682 10 mg as oral capsules under fasted conditions.

Arm type	Experimental
Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MK-3682 10 mg oral capsule x 1 day

Arm title	Group B - MK-3682 25 mg (Cohort 2b)

Arm description:

Participants were administered a single dose of MK-3682 25 mg as oral capsules under fasted conditions.

Arm type	Experimental
Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MK-3682 25 mg oral capsule x 1 day

Arm title	Group B - MK-3682 50 mg (Cohort 3b)

Arm description:

Participants were administered a single dose of MK-3682 50 mg as oral capsules under fasted conditions.

Arm type	Experimental

Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MK-3682 50 mg oral capsule x 1 day

Arm title	Group B - MK-3682 150 mg (Cohort 4b)

Arm description:

Participants were administered a single dose of MK-3682 150 mg as oral capsules under fasted conditions.

Arm type	Experimental
Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MK-3682 150 mg oral capsule x 1 day

Arm title	Group B - MK-3682 300 mg (Cohort 5b)

Arm description:

Participants were administered a single dose of MK-3682 300 mg as oral capsules under fasted conditions.

Arm type	Experimental
Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MK-3682 300 mg oral capsule x 1 day

Arm title	Groups C and D - MK-3682 50 mg (capsule)

Arm description:

Participants were administered single doses of MK-3682 50 mg as oral capsules once daily for 7 days under fasted conditions.

Arm type	Experimental
Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MK-3682 50 mg oral capsule QD x 7 days

Arm title	Groups C and D - MK-3682 150 mg (capsule)

Arm description:

Participants were administered single doses of MK-3682 150 mg as oral capsules once daily for 7 days under fasted conditions.

Arm type	Experimental

Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MK-3682 150 mg oral capsule QD x 7 days

Arm title	Group C - MK-3682 250 mg (capsule)

Arm description:

Participants were administered single doses of MK-3682 250 mg as oral capsules once daily for 7 days under fasted conditions.

Arm type	Experimental
Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MK-3682 250 mg oral capsule QD x 7 days

Arm title	Groups C and D - MK-3682 300 mg (capsule)

Arm description:

Participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.

Arm type	Experimental
Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MK-3682 300 mg oral capsule QD x 7 days

Arm title	Group C - MK-3682 400 mg (capsule)

Arm description:

Participants were administered single doses of MK-3682 400 mg as oral capsules once daily for 7 days under fasted conditions.

Arm type	Experimental
Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MK-3682 400 mg oral capsule QD x 7 days

Arm title	Group C - MK-3682 300 mg (tablet)

Arm description:

Participants were administered single doses of MK-3682 300 mg as oral tablets once daily for 7 days under fasted conditions.

Arm type	Experimental

Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

MK-3682 300 mg oral tablet QD x 7 days

Arm title	Group C - MK-3682 450 mg (tablet)

Arm description:

Participants were administered single doses of MK-3682 450 mg as oral tablets once daily for 7 days under fasted conditions.

Arm type	Experimental
Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

MK-3682 450 mg oral tablet QD x 7 days

Arm title	Groups C and D - Placebo (pooled) (capsule)

Arm description:

Participants were administered single doses of MK-3682-matching placebo as oral capsules once daily for 7 days under fasted conditions.

Arm type	Placebo
Investigational medicinal product name	MK-3682-matching placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule, Tablet
Routes of administration	Oral use

Dosage and administration details:

MK-3682-matching placebo oral capsule or oral tablet QD x 7 days

Arm title	Group E - MK-3682 150 mg (Cohort 1e) (capsule)

Arm description:

Participants were administered a single dose of MK-3682 150 mg as oral capsules under fasted conditions.

Arm type	Experimental
Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MK-3682 150 mg oral capsule x 1 day

Arm title	Group E - MK-3682 300 mg (Cohort 2e) (capsule)

Arm description:

Participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.

Arm type	Experimental

Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

MK-3682 300 mg oral capsule QD x 7 days

Arm title	Group E - MK-3682 450 mg (Cohort 3e) (tablet)

Arm description:

Participants were administered single doses of MK-3682 450 mg as oral tablets once daily for 7 days under fasted conditions.

Arm type	Experimental
Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

MK-3682 450 mg oral tablet QD x 7 days

Arm title	Group F - MK-3682 300 mg (tablet)

Arm description:

Participants were administered single doses of MK-3682 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered Itraconazole 200 mg as oral solution twice daily on Day -5 and 200 mg once daily from Day -4 to Day 11.

Arm type	Experimental
Investigational medicinal product name	MK-3682
Investigational medicinal product code	
Other name	IDX21437
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

MK-3682 300 mg oral tablet QD x 7 days

Investigational medicinal product name	itraconazole 200 mg
Investigational medicinal product code	
Other name	Sporanox®
Pharmaceutical forms	Oral solution
Routes of administration	Oral use

Dosage and administration details:

itraconazole 200 mg taken as either a 10 mg/mL oral solution or as 100 mg oral capsules QD x 11 days

Number of subjects in period 1	Group A - Placebo (Cohort 1a -Cohort 5a - pooled) (capsule)	Group A - MK-3682 10 mg (Cohort 1a) (capsule)	Group A - MK-3682 25 mg (Cohort 2a) (capsule)
Started	10	6	6
Treated	10	6	6
Completed	10	6	6
Not completed	0	0	0
Did Not Receive Treatment	-	-	-

Number of subjects in period 1	Group A - MK-3682 50 mg (Cohort 3a) (capsule)	Group A - MK-3682 150 mg (Cohort 4a) (capsule)	Group A - MK-3682 300 mg (Cohort 5a) (capsule)
Started	6	6	6
Treated	6	6	6
Completed	6	6	6
Not completed	0	0	0
Did Not Receive Treatment	-	-	-

Number of subjects in period 1	Group A - Placebo (Cohort 6a)	Group A - MK-3682 300 mg (Cohort 6a)	Group B - MK-3682 10 mg (Cohort 1b)
Started	2	6	3
Treated	2	6	3
Completed	2	6	3
Not completed	0	0	0
Did Not Receive Treatment	-	-	-

Number of subjects in period 1	Group B - MK-3682 25 mg (Cohort 2b)	Group B - MK-3682 50 mg (Cohort 3b)	Group B - MK-3682 150 mg (Cohort 4b)
Started	3	3	3
Treated	3	3	3
Completed	3	3	3
Not completed	0	0	0
Did Not Receive Treatment	-	-	-

Number of subjects in period 1	Group B - MK-3682 300 mg (Cohort 5b)	Groups C and D - MK-3682 50 mg (capsule)	Groups C and D - MK-3682 150 mg (capsule)
Started	3	13	13
Treated	3	11	10
Completed	3	11	10
Not completed	0	2	3
Did Not Receive Treatment	-	2	3

Number of subjects in period 1	Group C - MK-3682 250 mg (capsule)	Groups C and D - MK-3682 300 mg (capsule)	Group C - MK-3682 400 mg (capsule)
Started	10	19	9
Treated	8	18	8
Completed	8	18	8
Not completed	2	1	1
Did Not Receive Treatment	2	1	1

Number of subjects in period 1	Group C - MK-3682 300 mg (tablet)	Group C - MK-3682 450 mg (tablet)	Groups C and D - Placebo (pooled) (capsule)
Started	9	11	9
Treated	8	8	9
Completed	8	8	9
Not completed	1	3	0
Did Not Receive Treatment	1	3	-

Number of subjects in period 1	Group E - MK-3682 150 mg (Cohort 1e) (capsule)	Group E - MK-3682 300 mg (Cohort 2e) (capsule)	Group E - MK-3682 450 mg (Cohort 3e) (tablet)
Started	3	3	8
Treated	3	3	8
Completed	3	3	8
Not completed	0	0	0
Did Not Receive Treatment	-	-	-

Number of subjects in period 1	Group F - MK-3682 300 mg (tablet)
Started	8
Treated	8
Completed	8
Not completed	0
Did Not Receive Treatment	-

Baseline characteristics

Reporting groups

Reporting group title	Group A - Placebo (Cohort 1a -Cohort 5a - pooled) (capsule)
Reporting group description:	
Participants were administered a single dose of MK-3682-matching placebo as oral capsules under fasted conditions (Cohorts 1a, 2a, 3a, 5a); Participants were administered single doses of MK-3682-matching placebo as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods (Cohort 4a).	
Reporting group title	Group A - MK-3682 10 mg (Cohort 1a) (capsule)
Reporting group description:	
Participants were administered a single dose of MK-3682 10 mg as oral capsules under fasted conditions.	
Reporting group title	Group A - MK-3682 25 mg (Cohort 2a) (capsule)
Reporting group description:	
Participants were administered a single dose of MK-3682 25 mg as oral capsules under fasted conditions.	
Reporting group title	Group A - MK-3682 50 mg (Cohort 3a) (capsule)
Reporting group description:	
Participants were administered a single dose of MK-3682 50 mg as oral capsules under fasted conditions.	
Reporting group title	Group A - MK-3682 150 mg (Cohort 4a) (capsule)
Reporting group description:	
Participants were administered single doses of MK-3682 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.	
Reporting group title	Group A - MK-3682 300 mg (Cohort 5a) (capsule)
Reporting group description:	
Participants were administered a single dose of MK-3682 300 mg as oral capsules under fasted conditions.	
Reporting group title	Group A - Placebo (Cohort 6a)
Reporting group description:	
Participants were administered single doses of MK-3682-matching placebo as oral capsules for 7 days under fasted conditions.	
Reporting group title	Group A - MK-3682 300 mg (Cohort 6a)
Reporting group description:	
Participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.	
Reporting group title	Group B - MK-3682 10 mg (Cohort 1b)
Reporting group description:	
Participants were administered a single dose of MK-3682 10 mg as oral capsules under fasted conditions.	
Reporting group title	Group B - MK-3682 25 mg (Cohort 2b)
Reporting group description:	
Participants were administered a single dose of MK-3682 25 mg as oral capsules under fasted conditions.	
Reporting group title	Group B - MK-3682 50 mg (Cohort 3b)
Reporting group description:	
Participants were administered a single dose of MK-3682 50 mg as oral capsules under fasted conditions.	
Reporting group title	Group B - MK-3682 150 mg (Cohort 4b)
Reporting group description:	
Participants were administered a single dose of MK-3682 150 mg as oral capsules under fasted conditions.	
Reporting group title	Group B - MK-3682 300 mg (Cohort 5b)

Reporting group description:

Participants were administered a single dose of MK-3682 300 mg as oral capsules under fasted conditions.

Reporting group title	Groups C and D - MK-3682 50 mg (capsule)

Reporting group description:

Participants were administered single doses of MK-3682 50 mg as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Groups C and D - MK-3682 150 mg (capsule)

Reporting group description:

Participants were administered single doses of MK-3682 150 mg as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Group C - MK-3682 250 mg (capsule)

Reporting group description:

Participants were administered single doses of MK-3682 250 mg as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Groups C and D - MK-3682 300 mg (capsule)

Reporting group description:

Participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Group C - MK-3682 400 mg (capsule)

Reporting group description:

Participants were administered single doses of MK-3682 400 mg as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Group C - MK-3682 300 mg (tablet)

Reporting group description:

Participants were administered single doses of MK-3682 300 mg as oral tablets once daily for 7 days under fasted conditions.

Reporting group title	Group C - MK-3682 450 mg (tablet)

Reporting group description:

Participants were administered single doses of MK-3682 450 mg as oral tablets once daily for 7 days under fasted conditions.

Reporting group title	Groups C and D - Placebo (pooled) (capsule)

Reporting group description:

Participants were administered single doses of MK-3682-matching placebo as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Group E - MK-3682 150 mg (Cohort 1e) (capsule)

Reporting group description:

Participants were administered a single dose of MK-3682 150 mg as oral capsules under fasted conditions.

Reporting group title	Group E - MK-3682 300 mg (Cohort 2e) (capsule)

Reporting group description:

Participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Group E - MK-3682 450 mg (Cohort 3e) (tablet)

Reporting group description:

Participants were administered single doses of MK-3682 450 mg as oral tablets once daily for 7 days under fasted conditions.

Reporting group title	Group F - MK-3682 300 mg (tablet)

Reporting group description:

Participants were administered single doses of MK-3682 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered Itraconazole 200 mg as oral solution twice daily on Day -5 and 200 mg once daily from Day -4 to Day 11.

Reporting group values	Group A - Placebo (Cohort 1a -Cohort 5a - pooled) (capsule)	Group A - MK-3682 10 mg (Cohort 1a) (capsule)	Group A - MK-3682 25 mg (Cohort 2a) (capsule)
Number of subjects	10	6	6
Age Categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	10	6	6
From 65-84 years	0	0	0
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	35.3	29.2	33.3
standard deviation	± 7.7	± 7.4	± 15.1
Gender Categorical			
Units: Subjects			
Female	4	4	2
Male	6	2	4

Reporting group values	Group A - MK-3682 50 mg (Cohort 3a) (capsule)	Group A - MK-3682 150 mg (Cohort 4a) (capsule)	Group A - MK-3682 300 mg (Cohort 5a) (capsule)
Number of subjects	6	6	6
Age Categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	6	6	6
From 65-84 years	0	0	0
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	31.3	35.5	35.2
standard deviation	± 11.6	± 11.8	± 9.9
Gender Categorical			
Units: Subjects			
Female	3	5	4
Male	3	1	2

Reporting group values	Group A - Placebo (Cohort 6a)	Group A - MK-3682 300 mg (Cohort 6a)	Group B - MK-3682 10 mg (Cohort 1b)

Number of subjects	2	6	3
Age Categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	2	6	3
From 65-84 years	0	0	0
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	36	35.3	37
standard deviation	± 2.8	± 12.7	± 9.5
Gender Categorical Units: Subjects			
Female	0	4	0
Male	2	2	3

Reporting group values	Group B - MK-3682 25 mg (Cohort 2b)	Group B - MK-3682 50 mg (Cohort 3b)	Group B - MK-3682 150 mg (Cohort 4b)
Number of subjects	3	3	3
Age Categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	3	3	3
From 65-84 years	0	0	0
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	42.3	46.7	43.3
standard deviation	± 7.2	± 4.2	± 5.7
Gender Categorical Units: Subjects			
Female	0	1	2
Male	3	2	1

Reporting group values	Group B - MK-3682 300 mg (Cohort 5b)	Groups C and D - MK-3682 50 mg (capsule)	Groups C and D - MK-3682 150 mg (capsule)
Number of subjects	3	13	13

Age Categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	3	13	13
From 65-84 years	0	0	0
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	41.3	42	43.3
standard deviation	± 9	± 10	± 9.6
Gender Categorical Units: Subjects			
Female	1	6	0
Male	2	7	13

Reporting group values	Group C - MK-3682 250 mg (capsule)	Groups C and D - MK-3682 300 mg (capsule)	Group C - MK-3682 400 mg (capsule)
Number of subjects	10	19	9
Age Categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	9	19	9
From 65-84 years	1	0	0
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	44.4	40.1	44
standard deviation	± 12.1	± 11.4	± 8.2
Gender Categorical Units: Subjects			
Female	5	5	3
Male	5	14	6

Reporting group values	Group C - MK-3682 300 mg (tablet)	Group C - MK-3682 450 mg (tablet)	Groups C and D - Placebo (pooled) (capsule)
Number of subjects	9	11	9

Age Categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	9	11	9
From 65-84 years	0	0	0
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	41.3	44.6	43.7
standard deviation	± 11.2	± 10.5	± 7.7
Gender Categorical Units: Subjects			
Female	5	5	3
Male	4	6	6

Reporting group values	Group E - MK-3682 150 mg (Cohort 1e) (capsule)	Group E - MK-3682 300 mg (Cohort 2e) (capsule)	Group E - MK-3682 450 mg (Cohort 3e) (tablet)
Number of subjects	3	3	8
Age Categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	3	3	8
From 65-84 years	0	0	0
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	57	56.3	49.1
standard deviation	± 4.4	± 3.1	± 8
Gender Categorical Units: Subjects			
Female	0	0	1
Male	3	3	7

Reporting group values	Group F - MK-3682 300 mg (tablet)	Total	
Number of subjects	8	178	
Age Categorical Units: Subjects			
In utero	0	0	

Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	8	177	
From 65-84 years	0	1	
85 years and over	0	0	
Age Continuous			
Units: years			
arithmetic mean	43.1		
standard deviation	± 12.5	-	
Gender Categorical			
Units: Subjects			
Female	6	69	
Male	2	109	

End points

End points reporting groups

Reporting group title	Group A - Placebo (Cohort 1a -Cohort 5a - pooled) (capsule)
Reporting group description:	
Participants were administered a single dose of MK-3682-matching placebo as oral capsules under fasted conditions (Cohorts 1a, 2a, 3a, 5a); Participants were administered single doses of MK-3682-matching placebo as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods (Cohort 4a).	
Reporting group title	Group A - MK-3682 10 mg (Cohort 1a) (capsule)
Reporting group description:	
Participants were administered a single dose of MK-3682 10 mg as oral capsules under fasted conditions.	
Reporting group title	Group A - MK-3682 25 mg (Cohort 2a) (capsule)
Reporting group description:	
Participants were administered a single dose of MK-3682 25 mg as oral capsules under fasted conditions.	
Reporting group title	Group A - MK-3682 50 mg (Cohort 3a) (capsule)
Reporting group description:	
Participants were administered a single dose of MK-3682 50 mg as oral capsules under fasted conditions.	
Reporting group title	Group A - MK-3682 150 mg (Cohort 4a) (capsule)
Reporting group description:	
Participants were administered single doses of MK-3682 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.	
Reporting group title	Group A - MK-3682 300 mg (Cohort 5a) (capsule)
Reporting group description:	
Participants were administered a single dose of MK-3682 300 mg as oral capsules under fasted conditions.	
Reporting group title	Group A - Placebo (Cohort 6a)
Reporting group description:	
Participants were administered single doses of MK-3682-matching placebo as oral capsules for 7 days under fasted conditions.	
Reporting group title	Group A - MK-3682 300 mg (Cohort 6a)
Reporting group description:	
Participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.	
Reporting group title	Group B - MK-3682 10 mg (Cohort 1b)
Reporting group description:	
Participants were administered a single dose of MK-3682 10 mg as oral capsules under fasted conditions.	
Reporting group title	Group B - MK-3682 25 mg (Cohort 2b)
Reporting group description:	
Participants were administered a single dose of MK-3682 25 mg as oral capsules under fasted conditions.	
Reporting group title	Group B - MK-3682 50 mg (Cohort 3b)
Reporting group description:	
Participants were administered a single dose of MK-3682 50 mg as oral capsules under fasted conditions.	
Reporting group title	Group B - MK-3682 150 mg (Cohort 4b)
Reporting group description:	
Participants were administered a single dose of MK-3682 150 mg as oral capsules under fasted conditions.	
Reporting group title	Group B - MK-3682 300 mg (Cohort 5b)

Reporting group description:

Participants were administered a single dose of MK-3682 300 mg as oral capsules under fasted conditions.

Reporting group title	Groups C and D - MK-3682 50 mg (capsule)

Reporting group description:

Participants were administered single doses of MK-3682 50 mg as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Groups C and D - MK-3682 150 mg (capsule)

Reporting group description:

Participants were administered single doses of MK-3682 150 mg as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Group C - MK-3682 250 mg (capsule)

Reporting group description:

Participants were administered single doses of MK-3682 250 mg as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Groups C and D - MK-3682 300 mg (capsule)

Reporting group description:

Participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Group C - MK-3682 400 mg (capsule)

Reporting group description:

Participants were administered single doses of MK-3682 400 mg as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Group C - MK-3682 300 mg (tablet)

Reporting group description:

Participants were administered single doses of MK-3682 300 mg as oral tablets once daily for 7 days under fasted conditions.

Reporting group title	Group C - MK-3682 450 mg (tablet)

Reporting group description:

Participants were administered single doses of MK-3682 450 mg as oral tablets once daily for 7 days under fasted conditions.

Reporting group title	Groups C and D - Placebo (pooled) (capsule)

Reporting group description:

Participants were administered single doses of MK-3682-matching placebo as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Group E - MK-3682 150 mg (Cohort 1e) (capsule)

Reporting group description:

Participants were administered a single dose of MK-3682 150 mg as oral capsules under fasted conditions.

Reporting group title	Group E - MK-3682 300 mg (Cohort 2e) (capsule)

Reporting group description:

Participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Group E - MK-3682 450 mg (Cohort 3e) (tablet)

Reporting group description:

Participants were administered single doses of MK-3682 450 mg as oral tablets once daily for 7 days under fasted conditions.

Reporting group title	Group F - MK-3682 300 mg (tablet)

Reporting group description:

Participants were administered single doses of MK-3682 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered Itraconazole 200 mg as oral solution twice daily on Day -5 and 200 mg once daily from Day -4 to Day 11.

Subject analysis set title	Group A - Placebo (Cohort 1a -Cohort 5a - pooled) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682-matching placebo as oral capsules under fasted conditions (Cohorts 1a, 2a, 3a, 5a); Participants were administered single doses of MK-3682-

matching placebo as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods (Cohort 4a).

Subject analysis set title	Group A - MK-3682 10 mg (Cohort 1a) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682 10 mg as oral capsules under fasted conditions.

Subject analysis set title	Group A - MK-3682 25 mg (Cohort 2a) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682 25 mg as oral capsules under fasted conditions.

Subject analysis set title	Group A - MK-3682 50 mg (Cohort 3a) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682 50 mg as oral capsules under fasted conditions.

Subject analysis set title	Group A - MK-3682 150 mg (Cohort 4a) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.

Subject analysis set title	Group A - MK-3682 300 mg (Cohort 5a) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682 300 mg as oral capsules under fasted conditions.

Subject analysis set title	Group A - Placebo (Cohort 6a) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682-matching placebo oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Group A - MK-3682 300 mg (Cohort 6a) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Group B - MK-3682 10 mg (Cohort 1b) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682 10 mg as oral capsules under fasted conditions.

Subject analysis set title	Group B - MK-3682 25 mg (Cohort 2b) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682 25 mg as oral capsules under fasted conditions.

Subject analysis set title	Group B - MK-3682 50 mg (Cohort 3b) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682 50 mg oral capsules under fasted conditions.

Subject analysis set title	Group B - MK-3682 150 mg (Cohort 4b) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682 150 mg as oral capsules under fasted

conditions.

Subject analysis set title	Group B - MK-3682 300 mg (Cohort 5b) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682 300 mg oral capsules under fasted conditions.

Subject analysis set title	Groups C and D - Placebo (pooled) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants administered single doses of MK-3682-matching placebo as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Groups C and D - MK-3682 50 mg (capsule) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 50 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Groups C and D - MK-3682 150 mg (capsule) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 150 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Group C - MK-3682 250 mg (capsule) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 250 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Groups C and D - MK-3682 300 mg (capsule) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Group C - MK-3682 400 mg (capsule) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 400 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Group C - MK-3682 300 mg (tablet) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 300 mg as oral tablets once daily for 7 days under fasted conditions.

Subject analysis set title	Group C - MK-3682 450 mg (tablet) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 450 mg as oral tablets once daily for 7 days under fasted conditions.

Subject analysis set title	Group E - MK-3682 150 mg (Cohort 1e) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682 150 mg as oral capsules under fasted conditions.

Subject analysis set title	Group E - MK-3682 300 mg (Cohort 2e) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Group E - MK-3682 450 mg (Cohort 3e) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 450 mg as oral tablets once daily for 7 days under fasted conditions.

Subject analysis set title	Group F - MK-3682 300 mg (tablet) - AST
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered Itraconazole 200 mg twice daily as oral solution on Day -5 and 200 mg once daily from Day -4 to Day 11.

Subject analysis set title	Group A - MK-3682 10 mg (Cohort 1a) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682 10 mg as oral capsules under fasted conditions.

Subject analysis set title	Group A - MK-3682 25 mg (Cohort 2a) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682 25 mg as oral capsules under fasted conditions.

Subject analysis set title	Group A - MK-3682 50 mg (Cohort 3a) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682 50 mg as oral capsules under fasted conditions.

Subject analysis set title	Group A - MK-3682 150 mg (Cohort 4a) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.

Subject analysis set title	Group A - MK-3682 150 mg (Fed) (Cohort 4a) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.

Subject analysis set title	Group A - MK-3682 300 mg (Cohort 5a) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682 300 mg as oral capsules under fasted conditions.

Subject analysis set title	Group A - MK-3682 300 mg (Cohort 6a) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Group B - MK-3682 10 mg (Cohort 1b) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682 10 mg as oral capsules under fasted conditions.

Subject analysis set title	Group B - MK-3682 25 mg (Cohort 2b) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682 25 mg as oral capsules under fasted conditions.

Subject analysis set title	Group B - MK-3682 50 mg (Cohort 3b) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682 50 mg as oral capsules under fasted conditions.

Subject analysis set title	Group B - MK-3682 150 mg (Cohort 4b) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682 150 mg as oral capsules under fasted conditions.

Subject analysis set title	Group B - MK-3682 300 mg (Cohort 5b) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682 300 mg as oral capsules under fasted conditions.

Subject analysis set title	Groups C and D - MK-3682 50 mg (capsule) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Group C and D participants were administered single doses of MK-3682 50 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Groups C and D - MK-3682 150 mg (capsule) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Group C and D participants were administered single doses of MK-3682 150 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Group C - MK-3682 250 mg (capsule) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 250 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Groups C and D - MK-3682 300 mg (capsule) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Group C and D participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Group C - MK-3682 400 mg (capsule) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 400 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Group C - MK-3682 300 mg (tablet) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 300 mg as oral tablets once daily for 7 days under fasted conditions.

Subject analysis set title	Group C - MK-3682 450 mg (tablet) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 450 mg as oral tablets once daily for 7 days under fasted conditions.

Subject analysis set title	Group E - MK-3682 150 mg (Cohort 1e) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered a single dose of MK-3682 150 mg as oral capsules under fasted conditions.

Subject analysis set title	Group E - MK-3682 300 mg (Cohort 2e) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Group E - MK-3682 450 mg (Cohort 3e) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 450 mg as oral tablets once daily for 7 days under fasted conditions.

Subject analysis set title	Group F - MK-3682 300 mg (tablet) - PK
Subject analysis set type	Sub-group analysis

Subject analysis set description:

Participants were administered single doses of MK-3682 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered Itraconazole 200 mg twice daily as oral solution on day -5 and 200 mg once daily from day -4 to Day 11.

Subject analysis set title	Group B - MK-3682 300 mg (Cohort 4b) - PP
Subject analysis set type	Per protocol

Subject analysis set description:

Participants were administered a single dose of MK-3682 150 mg as oral capsules under fasted conditions.

Subject analysis set title	Groups C and D - Placebo (pooled) - PP
Subject analysis set type	Per protocol

Subject analysis set description:

Participants administered single doses of MK-3682-matching placebo as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Groups C and D - MK-3682 50 mg (capsule) - PP
Subject analysis set type	Per protocol

Subject analysis set description:

Participants were administered single doses of MK-3682 50 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Groups C and D - MK-3682 150 mg (capsule) - PP
Subject analysis set type	Per protocol

Subject analysis set description:

Participants were administered single doses of MK-3682 150 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Group C - MK-3682 250 mg (capsule) - PP
Subject analysis set type	Per protocol

Subject analysis set description:

Participants were administered single doses of MK-3682 250 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Groups C and D - MK-3682 300 mg (capsule) - PP
Subject analysis set type	Per protocol

Subject analysis set description:

Participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Group C - MK-3682 400 mg (capsule) - PP
Subject analysis set type	Per protocol

Subject analysis set description:

Participants were administered single doses of MK-3682 400 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Group C - MK-3682 300 mg (capsule) - PP
Subject analysis set type	Per protocol

Subject analysis set description:

Participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Group C - MK-3682 300 mg (tablet) - PP
Subject analysis set type	Per protocol

Subject analysis set description:

Participants were administered MK-3682 300 mg as oral tablets once daily for 7 days under fasted conditions.

Subject analysis set title	Group C - MK-3682 450 mg (tablet) - PP
Subject analysis set type	Per protocol

Subject analysis set description:

Participants were administered single doses of MK-3682 450 mg as oral tablets once daily for 7 days under fasted conditions.

Subject analysis set title	Group E - MK-3682 150 mg (Cohort 1e) - PP
Subject analysis set type	Per protocol

Subject analysis set description:

Participants were administered a single dose of MK-3682 150 mg as oral capsules under fasted conditions.

Subject analysis set title	Group E - MK-3682 300 mg (Cohort 2e) - PP
Subject analysis set type	Per protocol

Subject analysis set description:

Participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.

Subject analysis set title	Group E - MK-3682 450 mg (Cohort 3e) - PP
Subject analysis set type	Per protocol

Subject analysis set description:

Participants were administered single doses of MK-3682 450 mg as oral tablets once daily for 7 days under fasted conditions.

Primary: Percentage of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (AE)

End point title	Percentage of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (AE)[1]

End point description:

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product that does not necessarily have a causal relationship with the study drug(s). An AE can therefore be any unfavorable and unintended sign (including an abnormal lab finding), symptom, or disease temporally associated with the use of study drug(s), whether or not related to study drugs(s). All Participants as Treated (APaT) Population: all participants who received at least one dose of the study drug. For Cohort 4a, only participants on the fasted regimen are included.

End point type	Primary

End point timeframe:

Up to 42 days

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - Placebo (Cohort 1a - Cohort 5a - pooled) - AST	Group A - MK-3682 10 mg (Cohort 1a) - AST	Group A - MK-3682 25 mg (Cohort 2a) - AST	Group A - MK-3682 50 mg (Cohort 3a) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	10	6	6	6
Units: Participants				
number (not applicable)	50	0	33.3	33.3

End point values	Group A - MK-3682 150 mg (Cohort 4a) - AST	Group A - MK-3682 300 mg (Cohort 5a) - AST	Group A - Placebo (Cohort 6a) - AST	Group A - MK-3682 300 mg (Cohort 6a) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	6	2	6
Units: Participants				
number (not applicable)	66.7	50	50	33.3

End point values	Group B - MK-3682 10 mg (Cohort 1b) - AST	Group B - MK-3682 25 mg (Cohort 2b) - AST	Group B - MK-3682 50 mg (Cohort 3b) - AST	Group B - MK-3682 150 mg (Cohort 4b) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3	3	3	3
Units: Participants				
number (not applicable)	33.3	66.7	33.3	66.7

End point values	Group B - MK-3682 300 mg (Cohort 5b) - AST	Groups C and D - Placebo (pooled) - AST	Groups C and D - MK-3682 50 mg (capsule) - AST	Groups C and D - MK-3682 150 mg (capsule) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3	9	11	10
Units: Participants				
number (not applicable)	66.7	66.7	72.7	70

End point values	Group C - MK-3682 250 mg (capsule) - AST	Groups C and D - MK-3682 300 mg (capsule) - AST	Group C - MK-3682 400 mg (capsule) - AST	Group C - MK-3682 300 mg (tablet) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	8	18	8	8
Units: Participants				
number (not applicable)	87.5	44.4	62.5	75

End point values	Group C - MK-3682 450 mg (tablet) - AST	Group E - MK-3682 150 mg (Cohort 1e) - AST	Group E - MK-3682 300 mg (Cohort 2e) - AST	Group E - MK-3682 450 mg (Cohort 3e) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	8	3	3	8

Units: Participants				
number (not applicable)	62.5	0	100	62.5

End point values	Group F - MK-3682 300 mg (tablet) - AST			
Subject group type	Subject analysis set			
Number of subjects analysed	8			
Units: Participants				
number (not applicable)	37.5			

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants Who Experienced at Least One Serious Treatment-Emergent Adverse Event (SAE)

End point title	Percentage of Participants Who Experienced at Least One Serious Treatment-Emergent Adverse Event (SAE)[2]

End point description:

An SAE is defined as any untoward medical occurrence that at any dose: Results in death - this includes deaths that appear to be completely unrelated to study drug (e.g., car accident); Is life-threatening - a life-threatening AE is any AE that places the participant, in the view of the investigator, at immediate risk of death from the reaction as it occurred; Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent or significant disability/incapacity; Is a congenital anomaly/birth defect; Is an important medical event. APaT Population: all participants who received at least one dose of the study drug. For Cohort 4a, only participants on the fasted regimen are included.

End point type	Primary

End point timeframe:

Up to 42 days

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - Placebo (Cohort 1a - Cohort 5a - pooled) - AST	Group A - MK-3682 10 mg (Cohort 1a) - AST	Group A - MK-3682 25 mg (Cohort 2a) - AST	Group A - MK-3682 50 mg (Cohort 3a) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	10	6	6	6
Units: Participants				
number (not applicable)	0	0	0	0

End point values	Group A - MK-3682 150 mg (Cohort 4a) - AST	Group A - MK-3682 300 mg (Cohort 5a) - AST	Group A - Placebo (Cohort 6a) - AST	Group A - MK-3682 300 mg (Cohort 6a) - AST

Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	6	2	6
Units: Participants				
number (not applicable)	0	0	0	0

End point values	Group B - MK-3682 10 mg (Cohort 1b) - AST	Group B - MK-3682 25 mg (Cohort 2b) - AST	Group B - MK-3682 50 mg (Cohort 3b) - AST	Group B - MK-3682 150 mg (Cohort 4b) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3	3	3	3
Units: Participants				
number (not applicable)	0	0	0	0

End point values	Group B - MK-3682 300 mg (Cohort 5b) - AST	Groups C and D - Placebo (pooled) - AST	Groups C and D - MK-3682 50 mg (capsule) - AST	Groups C and D - MK-3682 150 mg (capsule) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3	9	11	10
Units: Participants				
number (not applicable)	0	0	0	0

End point values	Group C - MK-3682 250 mg (capsule) - AST	Groups C and D - MK-3682 300 mg (capsule) - AST	Group C - MK-3682 400 mg (capsule) - AST	Group C - MK-3682 300 mg (tablet) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	8	18	8	8
Units: Participants				
number (not applicable)	0	0	0	0

End point values	Group C - MK-3682 450 mg (tablet) - AST	Group E - MK-3682 150 mg (Cohort 1e) - AST	Group E - MK-3682 300 mg (Cohort 2e) - AST	Group E - MK-3682 450 mg (Cohort 3e) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	8	3	3	8
Units: Participants				
number (not applicable)	0	0	0	0

End point values	Group F - MK-			

	3682 300 mg (tablet) - AST			
Subject group type	Subject analysis set			
Number of subjects analysed	8			
Units: Participants				
number (not applicable)	0			

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants Who Experienced Treatment-Emergent Dose-Limiting Toxicity (DLT)

End point title	Percentage of Participants Who Experienced Treatment-Emergent Dose-Limiting Toxicity (DLT)[3]

End point description:

A DLT is defined as the occurrence of any of the following events after administration of the study drug: any SAE considered by the investigator to be at least reasonably or possibly related to the study drug; any ≥ Grade 3 clinical AE considered by the investigator to be at least reasonably or possibly related to the study drug; any ≥ Grade 3 confirmed lab abnormalities considered by the investigator to be at least reasonably or possibly related to the study drug (except for asymptomatic Grade 3/4 cholesterol and triglyceride); any clinical or lab AE of any intensity that is considered by the investigator to be at least reasonably or possibly related to study drug that necessitates permanent discontinuation of study drug; and confirmed increase in QTcF≥60 ms over Baseline or absolute QTcF≥500 ms. APaT Population: all participants who received at least one dose of the study drug. For Cohort 4a, only participants on the fasted regimen are included.

End point type	Primary

End point timeframe:

Up to 13 days

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - Placebo (Cohort 1a - Cohort 5a - pooled) - AST	Group A - MK-3682 10 mg (Cohort 1a) - AST	Group A - MK-3682 25 mg (Cohort 2a) - AST	Group A - MK-3682 50 mg (Cohort 3a) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	10	6	6	6
Units: Participants				
number (not applicable)	0	0	0	0

End point values	Group A - MK-3682 150 mg (Cohort 4a) - AST	Group A - MK-3682 300 mg (Cohort 5a) - AST	Group A - Placebo (Cohort 6a) - AST	Group A - MK-3682 300 mg (Cohort 6a) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	6	2	6
Units: Participants				
number (not applicable)	0	0	0	0

End point values	Group B - MK-3682 10 mg (Cohort 1b) - AST	Group B - MK-3682 25 mg (Cohort 2b) - AST	Group B - MK-3682 50 mg (Cohort 3b) - AST	Group B - MK-3682 150 mg (Cohort 4b) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3	3	3	3
Units: Participants				
number (not applicable)	0	0	0	0

End point values	Group B - MK-3682 300 mg (Cohort 5b) - AST	Groups C and D - Placebo (pooled) - AST	Groups C and D - MK-3682 50 mg (capsule) - AST	Groups C and D - MK-3682 150 mg (capsule) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3	9	11	10
Units: Participants				
number (not applicable)	0	0	9.1	10

End point values	Group C - MK-3682 250 mg (capsule) - AST	Groups C and D - MK-3682 300 mg (capsule) - AST	Group C - MK-3682 400 mg (capsule) - AST	Group C - MK-3682 300 mg (tablet) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	8	18	8	8
Units: Participants				
number (not applicable)	0	5.6	0	0

End point values	Group C - MK-3682 450 mg (tablet) - AST	Group E - MK-3682 150 mg (Cohort 1e) - AST	Group E - MK-3682 300 mg (Cohort 2e) - AST	Group E - MK-3682 450 mg (Cohort 3e) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	8	3	3	8
Units: Participants				
number (not applicable)	0	0	0	0

End point values	Group F - MK-3682 300 mg (tablet) - AST			
Subject group type	Subject analysis set			
Number of subjects analysed	8			
Units: Participants				

number (not applicable)	0			

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants Who Experienced at Least One Grade 1, 2, 3, 4 or 5 Laboratory Abnormality

End point title	Percentage of Participants Who Experienced at Least One Grade 1, 2, 3, 4 or 5 Laboratory Abnormality[4]

End point description:

Laboratory abnormalities were graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. Grade 1: Mild TEAE as Worst Severity; Grade 2: Moderate TEAE as Worst Severity; Grade 3: Severe TEAE as Worst Severity; Grade 4: Potentially Life-Threatening TEAE as Worst Severity; Grade 5: TEAE Leading to Death. APaT Population: all participants who received at least one dose of the study drug. For Cohort 4a, only participants on the fasted regimen are included.

End point type	Primary

End point timeframe:

Up to 42 days

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - Placebo (Cohort 1a - Cohort 5a - pooled) - AST	Group A - MK-3682 10 mg (Cohort 1a) - AST	Group A - MK-3682 25 mg (Cohort 2a) - AST	Group A - MK-3682 50 mg (Cohort 3a) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	10	6	6	6
Units: Participants				
number (not applicable)				
Grade 1	50	0	16.7	16.7
Grade 2	0	0	16.7	16.7
Grade 3	0	0	0	0
Grade 4	0	0	0	0
Grade 5	0	0	0	0

End point values	Group A - MK-3682 150 mg (Cohort 4a) - AST	Group A - MK-3682 300 mg (Cohort 5a) - AST	Group A - Placebo (Cohort 6a) - AST	Group A - MK-3682 300 mg (Cohort 6a) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	6	2	6
Units: Participants				
number (not applicable)				
Grade 1	50	33.3	50	33.3

Grade 2	16.7	16.7	0	0
Grade 3	0	0	0	0
Grade 4	0	0	0	0
Grade 5	0	0	0	0

End point values	Group B - MK-3682 10 mg (Cohort 1b) - AST	Group B - MK-3682 25 mg (Cohort 2b) - AST	Group B - MK-3682 50 mg (Cohort 3b) - AST	Group B - MK-3682 150 mg (Cohort 4b) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3	3	3	3
Units: Participants				
number (not applicable)				
Grade 1	0	66.7	33.3	66.7
Grade 2	0	0	0	0
Grade 3	33.3	0	0	0
Grade 4	0	0	0	0
Grade 5	0	0	0	0

End point values	Group B - MK-3682 300 mg (Cohort 5b) - AST	Groups C and D - Placebo (pooled) - AST	Groups C and D - MK-3682 50 mg (capsule) - AST	Groups C and D - MK-3682 150 mg (capsule) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3	9	11	10
Units: Participants				
number (not applicable)				
Grade 1	66.7	33.3	45.5	60
Grade 2	0	33.3	18.2	0
Grade 3	0	0	9.1	10
Grade 4	0	0	0	0
Grade 5	0	0	0	0

End point values	Group C - MK-3682 250 mg (capsule) - AST	Groups C and D - MK-3682 300 mg (capsule) - AST	Group C - MK-3682 400 mg (capsule) - AST	Group C - MK-3682 300 mg (tablet) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	8	18	8	8
Units: Participants				
number (not applicable)				
Grade 1	37.5	33.3	0	37.5
Grade 2	50	5.6	62.5	37.5
Grade 3	0	5.6	0	0
Grade 4	0	0	0	0
Grade 5	0	0	0	0

End point values	Group C - MK-3682 450 mg (tablet) - AST	Group E - MK-3682 150 mg (Cohort 1e) - AST	Group E - MK-3682 300 mg (Cohort 2e) - AST	Group E - MK-3682 450 mg (Cohort 3e) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	8	3	3	8
Units: Participants				
number (not applicable)				
Grade 1	25	0	100	12.5
Grade 2	25	0	0	37.5
Grade 3	0	0	0	12.5
Grade 4	12.5	0	0	0
Grade 5	0	0	0	0

End point values	Group F - MK-3682 300 mg (tablet) - AST			
Subject group type	Subject analysis set			
Number of subjects analysed	8			
Units: Participants				
number (not applicable)				
Grade 1	0			
Grade 2	37.5			
Grade 3	0			
Grade 4	0			
Grade 5	0			

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of Participants With at Least One Treatment-Emergent AE for Which Study Treatment Was Withdrawn

End point title	Percentage of Participants With at Least One Treatment-Emergent AE for Which Study Treatment Was Withdrawn[5]

End point description:

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product, that does not necessarily have a causal relationship with the study drug(s). An AE can therefore be any unfavorable and unintended sign (including an abnormal lab finding), symptom, or disease temporally associated with the use of study drug(s), whether or not related to study drugs(s). APaT Population: all participants who received at least one dose of the study drug. For Cohort 4a, only participants on the fasted regimen are included.

End point type	Primary

End point timeframe:

Up to 13 days

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - Placebo (Cohort 1a - Cohort 5a - pooled) - AST	Group A - MK-3682 10 mg (Cohort 1a) - AST	Group A - MK-3682 25 mg (Cohort 2a) - AST	Group A - MK-3682 50 mg (Cohort 3a) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	10	6	6	6
Units: Participants				
number (not applicable)	0	0	0	0

End point values	Group A - MK-3682 150 mg (Cohort 4a) - AST	Group A - MK-3682 300 mg (Cohort 5a) - AST	Group A - Placebo (Cohort 6a) - AST	Group A - MK-3682 300 mg (Cohort 6a) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	6	2	6
Units: Participants				
number (not applicable)	0	0	0	0

End point values	Group B - MK-3682 10 mg (Cohort 1b) - AST	Group B - MK-3682 25 mg (Cohort 2b) - AST	Group B - MK-3682 50 mg (Cohort 3b) - AST	Group B - MK-3682 150 mg (Cohort 4b) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3	3	3	3
Units: Participants				
number (not applicable)	0	0	0	0

End point values	Group B - MK-3682 300 mg (Cohort 5b) - AST	Groups C and D - Placebo (pooled) - AST	Groups C and D - MK-3682 50 mg (capsule) - AST	Groups C and D - MK-3682 150 mg (capsule) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3	9	11	10
Units: Participants				
number (not applicable)	0	0	0	0

End point values	Group C - MK-3682 250 mg (capsule) - AST	Groups C and D - MK-3682 300 mg (capsule) - AST	Group C - MK-3682 400 mg (capsule) - AST	Group C - MK-3682 300 mg (tablet) - AST

Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	8	18	8	8
Units: Participants				
number (not applicable)	0	0	0	0

End point values	Group C - MK-3682 450 mg (tablet) - AST	Group E - MK-3682 150 mg (Cohort 1e) - AST	Group E - MK-3682 300 mg (Cohort 2e) - AST	Group E - MK-3682 450 mg (Cohort 3e) - AST
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	8	3	3	8
Units: Participants				
number (not applicable)	0	0	0	0

End point values	Group F - MK-3682 300 mg (tablet) - AST			
Subject group type	Subject analysis set			
Number of subjects analysed	8			
Units: Participants				
number (not applicable)	0			

Statistical analyses

No statistical analyses for this end point

Primary: Area Under the Plasma Drug Concentration-Time Curve from Time Zero to Last Measurable Concentration (AUC0-t) of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Healthy Participants (Group A)

End point title	Area Under the Plasma Drug Concentration-Time Curve from Time Zero to Last Measurable Concentration (AUC0-t) of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Healthy Participants (Group A)[6]

End point description:

AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). All participants are fasted. Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 10 mg (Cohort 1a) - PK	Group A - MK-3682 25 mg (Cohort 2a) - PK	Group A - MK-3682 50 mg (Cohort 3a) - PK	Group A - MK-3682 150 mg (Cohort 4a) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	6	6	6
Units: h·umol/L				
geometric mean (geometric coefficient of variation)	0.041 (± 32.7)	0.0837 (± 27.9)	0.246 (± 63.2)	1.67 (± 62.7)

End point values	Group A - MK-3682 300 mg (Cohort 5a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: h·umol/L				
geometric mean (geometric coefficient of variation)	2.78 (± 37.7)			

Statistical analyses

No statistical analyses for this end point

Primary: AUC0-t of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Fed State in Healthy Participants (Group A – Cohort 4a)

End point title	AUC0-t of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Fed State in Healthy Participants (Group A – Cohort 4a)[7]

End point description:

AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 150 mg (Fed) (Cohort 4a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: h·umol/L				
geometric mean (geometric coefficient of variation)	1.05 (± 48.5)			

Statistical analyses

No statistical analyses for this end point

Primary: AUC0-t of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A – Cohort 6a)

End point title	AUC0-t of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A – Cohort 6a)[8]

End point description:

AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 300 mg (Cohort 6a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: h·umol/L				
geometric mean (geometric coefficient of variation)				
Day 1	3.62 (± 34)			
Day 7	3.77 (± 21.7)			

Statistical analyses

No statistical analyses for this end point

Primary: AUC0-t of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)

End point title	AUC0-t of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)[9]

End point description:

AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable

concentration. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose. 99999 = Not Collected.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group B - MK-3682 10 mg (Cohort 1b) - PK	Group B - MK-3682 25 mg (Cohort 2b) - PK	Group B - MK-3682 50 mg (Cohort 3b) - PK	Group B - MK-3682 150 mg (Cohort 4b) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3	3	3	2
Units: h·umol/L				
geometric mean (geometric coefficient of variation)	0.064 (± 39.8)	0.228 (± 49.1)	0.341 (± 20.4)	1.17 (± 99999)

End point values	Group B - MK-3682 300 mg (Cohort 5b) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	3			
Units: h·umol/L				
geometric mean (geometric coefficient of variation)	1.39 (± 35.4)			

Statistical analyses

No statistical analyses for this end point

Primary: AUC0-t of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)

End point title	AUC0-t of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)[10]

End point description:

AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Groups C and D - MK-3682 50 mg (capsule) - PK	Groups C and D - MK-3682 150 mg (capsule) - PK	Group C - MK-3682 250 mg (capsule) - PK	Groups C and D - MK-3682 300 mg (capsule) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	10	9	8	17
Units: h·umol/L				
geometric mean (geometric coefficient of variation)				
Day 1	0.394 (± 51.4)	1.01 (± 52.9)	2.74 (± 36.5)	2.8 (± 45.4)
Day 7	0.347 (± 36.2)	0.935 (± 36.7)	2.37 (± 43.6)	2.42 (± 46.8)

End point values	Group C - MK-3682 400 mg (capsule) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	7			
Units: h·umol/L				
geometric mean (geometric coefficient of variation)				
Day 1	5.54 (± 40.1)			
Day 7	4.59 (± 22.1)			

Statistical analyses

No statistical analyses for this end point

Primary: AUC0-t of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)

End point title	AUC0-t of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)[11]

End point description:

AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group C - MK-3682 300 mg (tablet) - PK	Group C - MK-3682 450 mg (tablet) - PK		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	7	7		
Units: h·umol/L				
geometric mean (geometric coefficient of variation)				
Day 1	2 (± 51.7)	3.11 (± 45)		
Day 7	1.82 (± 43.9)	2.88 (± 30.4)		

Statistical analyses

No statistical analyses for this end point

Primary: AUC0-t of MK-3682 after Single Dose of MK-3682 as Capsule Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)

End point title	AUC0-t of MK-3682 after Single Dose of MK-3682 as Capsule Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)[12]

End point description:

AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose. 99999 = Not Calculated.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group E - MK-3682 150 mg (Cohort 1e) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	2			
Units: h·umol/L				
geometric mean (geometric coefficient of variation)	1.05 (± 99999)			

Statistical analyses

No statistical analyses for this end point

Primary: AUC0-t of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants with Mildly

Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)

End point title	AUC0-t of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)[13]

End point description:

AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group E - MK-3682 300 mg (Cohort 2e) - PK	Group E - MK-3682 450 mg (Cohort 3e) - PK		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	3	7		
Units: h·umol/L				
geometric mean (geometric coefficient of variation)				
Day 1	3.19 (± 32.8)	4.21 (± 35.2)		
Day 7	2.31 (± 31.8)	3.51 (± 23.2)		

Statistical analyses

No statistical analyses for this end point

Primary: AUC0-t of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as Tablet Formulation in Genotype 1, HCV-Infected Participants, with Itraconazole (Group F)

End point title	AUC0-t of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as Tablet Formulation in Genotype 1, HCV-Infected Participants, with Itraconazole (Group F)[14]

End point description:

AUC0-t was calculated using linear log trapezoidal summation from time zero to last measurable concentration. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group F - MK-3682 300 mg (tablet) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	8			
Units: h·umol/L				
geometric mean (geometric coefficient of variation)				
Day 1	10.6 (± 44)			
Day 7	9.39 (± 46.1)			

Statistical analyses

No statistical analyses for this end point

Primary: Maximum (Peak) Observed Plasma Drug Concentration (Cmax) of MK-3682 After Single Dose of MK-3682 as the Capsule Formulation in Healthy Participants (Group A)

End point title	Maximum (Peak) Observed Plasma Drug Concentration (Cmax) of MK-3682 After Single Dose of MK-3682 as the Capsule Formulation in Healthy Participants (Group A)[15]

End point description:

Maximum observed plasma drug concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). All participants are fasted. Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 10 mg (Cohort 1a) - PK	Group A - MK-3682 25 mg (Cohort 2a) - PK	Group A - MK-3682 50 mg (Cohort 3a) - PK	Group A - MK-3682 150 mg (Cohort 4a) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	6	6	6
Units: nmol/L				
geometric mean (geometric coefficient of variation)	29.6 (± 45.3)	47.7 (± 54.4)	119 (± 89.2)	1120 (± 47.8)

End point values	Group A - MK-3682 300 mg			

	(Cohort 5a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: nmol/L				
geometric mean (geometric coefficient of variation)	1530 (± 53.6)			

Statistical analyses

No statistical analyses for this end point

Primary: Cmax of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Fed State in Healthy Participants (Group A – Cohort 4a)

End point title	Cmax of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Fed State in Healthy Participants (Group A – Cohort 4a)[16]

End point description:

Maximum observed plasma drug concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[16] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 150 mg (Fed) (Cohort 4a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: nmol/L				
geometric mean (geometric coefficient of variation)	293 (± 63)			

Statistical analyses

No statistical analyses for this end point

Primary: Cmax of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A – Cohort 6a)

End point title	Cmax of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A – Cohort 6a)[17]

End point description:

Maximum observed plasma drug concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 300 mg (Cohort 6a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: nmol/L				
geometric mean (geometric coefficient of variation)				
Day 1	2300 (± 26.6)			
Day 7	2320 (± 19.9)			

Statistical analyses

No statistical analyses for this end point

Primary: Cmax of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)

End point title	Cmax of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)[18]

End point description:

Maximum observed plasma drug concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose. 99999 = Not Calculated.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[18] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group B - MK-3682 10 mg (Cohort 1b) - PK	Group B - MK-3682 25 mg (Cohort 2b) - PK	Group B - MK-3682 50 mg (Cohort 3b) - PK	Group B - MK-3682 150 mg (Cohort 4b) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3	3	3	2
Units: nmol/L				
geometric mean (geometric coefficient of variation)	43.6 (± 60.7)	122 (± 26.4)	168 (± 11.4)	510 (± 99999)

End point values	Group B - MK-3682 300 mg (Cohort 5b) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	3			
Units: nmol/L				
geometric mean (geometric coefficient of variation)	667 (± 15.3)			

Statistical analyses

No statistical analyses for this end point

Primary: Cmax of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)

End point title	Cmax of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)[19]

End point description:

Maximum observed plasma drug concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Groups C and D - MK-3682 50 mg (capsule) - PK	Groups C and D - MK-3682 150 mg (capsule) - PK	Group C - MK-3682 250 mg (capsule) - PK	Groups C and D - MK-3682 300 mg (capsule) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	10	9	8	17
Units: nmol/L				
geometric mean (geometric coefficient				

of variation)				
Day 1	286 (± 77.1)	524 (± 80.1)	1630 (± 58.1)	1360 (± 55.5)
Day 7	199 (± 45.6)	587 (± 34.9)	1250 (± 37.8)	1200 (± 59.4)

End point values	Group C - MK-3682 400 mg (capsule) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	7			
Units: nmol/L				
geometric mean (geometric coefficient of variation)				
Day 1	2320 (± 50.2)			
Day 7	2490 (± 25.7)			

Statistical analyses

No statistical analyses for this end point

Primary: Cmax of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)

End point title	Cmax of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)[20]

End point description:

Maximum observed plasma drug concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[20] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group C - MK-3682 300 mg (tablet) - PK	Group C - MK-3682 450 mg (tablet) - PK		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	7	7		
Units: nmol/L				
geometric mean (geometric coefficient of variation)				
Day 1	618 (± 45.2)	778 (± 29.7)		
Day 7	537 (± 56.4)	717 (± 47.2)		

Statistical analyses

No statistical analyses for this end point

Primary: Cmax of MK-3682 after Single Dose of MK-3682 as Capsule Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)

End point title	Cmax of MK-3682 after Single Dose of MK-3682 as Capsule Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)[21]

End point description:

Maximum observed plasma drug concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose. 99999 = Not Calculated.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group E - MK-3682 150 mg (Cohort 1e) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	2			
Units: nmol/L				
geometric mean (geometric coefficient of variation)	613 (± 99999)			

Statistical analyses

No statistical analyses for this end point

Primary: Cmax of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)

End point title	Cmax of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)[22]

End point description:

Maximum observed plasma drug concentration was obtained. PK Population: a subpopulation of the per-

protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[22] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group E - MK-3682 300 mg (Cohort 2e) - PK	Group E - MK-3682 450 mg (Cohort 3e) - PK		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	3	7		
Units: nmol/L				
geometric mean (geometric coefficient of variation)				
Day 1	1440 (± 35.9)	1090 (± 34.4)		
Day 7	1550 (± 47.5)	929 (± 26.6)		

Statistical analyses

No statistical analyses for this end point

Primary: Cmax of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as Tablet Formulation in Genotype 1, HCV-Infected Participants, with Itraconazole (Group F)

End point title	Cmax of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as Tablet Formulation in Genotype 1, HCV-Infected Participants, with Itraconazole (Group F)[23]

End point description:

Maximum observed plasma drug concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[23] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group F - MK-3682 300 mg (tablet) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	8			
Units: nmol/L				
geometric mean (geometric coefficient of variation)				
Day 1	2140 (± 39.4)			
Day 7	1910 (± 42.6)			

Statistical analyses

No statistical analyses for this end point

Primary: Time to Maximum Plasma Concentration (Tmax) of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Heathy Participants (Group A)

End point title	Time to Maximum Plasma Concentration (Tmax) of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Heathy Participants (Group A)[24]

End point description:

Time to maximum plasma concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). All participants are fasted. Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[24] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 10 mg (Cohort 1a) - PK	Group A - MK-3682 25 mg (Cohort 2a) - PK	Group A - MK-3682 50 mg (Cohort 3a) - PK	Group A - MK-3682 150 mg (Cohort 4a) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	6	6	6
Units: hr				
median (full range (min-max))	0.8 (0.5 to 1.05)	1 (0.5 to 3)	1 (0.5 to 1)	0.76 (0.5 to 2)

End point values	Group A - MK-3682 300 mg (Cohort 5a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: hr				
median (full range (min-max))	0.5 (0.5 to 2)			

Statistical analyses

No statistical analyses for this end point

Primary: Tmax of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Fed State in Healthy Participants (Group A- Cohort 4a)

End point title	Tmax of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Fed State in Healthy Participants (Group A- Cohort 4a)[25]

End point description:

Time to maximum plasma concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[25] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 150 mg (Fed) (Cohort 4a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: hr				
median (full range (min-max))	3.04 (3 to 4.05)			

Statistical analyses

No statistical analyses for this end point

Primary: Tmax of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A – Cohort 6a)

End point title	Tmax of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A – Cohort 6a)[26]

End point description:

Time to maximum plasma concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72,

96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[26] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 300 mg (Cohort 6a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: hr				
median (full range (min-max))				
Day 1	0.75 (0.5 to 1)			
Day 7	0.5 (0.5 to 2.03)			

Statistical analyses

No statistical analyses for this end point

Primary: Tmax of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Genotype 1, HCV-infected Participants (Group B)

End point title	Tmax of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Genotype 1, HCV-infected Participants (Group B)[27]

End point description:

Time to maximum plasma concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[27] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group B - MK-3682 10 mg (Cohort 1b) - PK	Group B - MK-3682 25 mg (Cohort 2b) - PK	Group B - MK-3682 50 mg (Cohort 3b) - PK	Group B - MK-3682 150 mg (Cohort 4b) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3	3	3	2
Units: hr				
median (full range (min-max))	0.5 (0.5 to 1)	1 (0.53 to 1)	1 (0.68 to 1)	0.76 (0.52 to 1)

End point values	Group B - MK-3682 300 mg (Cohort 5b) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	3			
Units: hr				
median (full range (min-max))	1 (0.5 to 1.08)			

Statistical analyses

No statistical analyses for this end point

Primary: Tmax of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-infected Participants (Groups C and D)

End point title	Tmax of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-infected Participants (Groups C and D)[28]

End point description:

Time to maximum plasma concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[28] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Groups C and D - MK-3682 50 mg (capsule) - PK	Groups C and D - MK-3682 150 mg (capsule) - PK	Group C - MK-3682 250 mg (capsule) - PK	Groups C and D - MK-3682 300 mg (capsule) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	10	9	8	17
Units: hr				
median (full range (min-max))				
Day 1	0.85 (0.5 to 2.03)	0.5 (0.5 to 2)	0.75 (0.5 to 2)	1 (0.5 to 4)
Day 7	0.97 (0.5 to 1)	0.5 (0.5 to 1)	1 (0.5 to 2)	0.5 (0.48 to 3)

End point values	Group C - MK-3682 400 mg			

	(capsule) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	7			
Units: hr				
median (full range (min-max))				
Day 1	0.5 (0.5 to 2)			
Day 7	0.5 (0.5 to 3)			

Statistical analyses

No statistical analyses for this end point

Primary: Tmax of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants (Group C)

End point title	Tmax of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants (Group C)[29]

End point description:

Time to maximum plasma concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[29] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group C - MK-3682 300 mg (tablet) - PK	Group C - MK-3682 450 mg (tablet) - PK		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	7	7		
Units: hr				
median (full range (min-max))				
Day 1	1 (0.5 to 4)	2 (0.5 to 3)		
Day 7	0.5 (0.5 to 3)	0.5 (0.5 to 3)		

Statistical analyses

No statistical analyses for this end point

Primary: Tmax of MK-3682 after Singe Dose of MK-3682 as Capsule Formulation in Genotype 1, HCV-infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)

End point title	Tmax of MK-3682 after Singe Dose of MK-3682 as Capsule

	Formulation in Genotype 1, HCV-infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)[30]

End point description:

Time to maximum plasma concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[30] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group E - MK-3682 150 mg (Cohort 1e) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	2			
Units: hr				
median (full range (min-max))	0.75 (0.5 to 1)			

Statistical analyses

No statistical analyses for this end point

Primary: Tmax of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)

End point title	Tmax of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)[31]

End point description:

Time to maximum plasma concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[31] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group E - MK-3682 300 mg (Cohort 2e) - PK	Group E - MK-3682 450 mg (Cohort 3e) - PK		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	3	7		
Units: hr				
median (full range (min-max))				
Day 1	1 (0.5 to 3)	1 (0.5 to 2)		
Day 7	1 (0.5 to 1)	1 (0.5 to 2)		

Statistical analyses

No statistical analyses for this end point

Primary: Tmax of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants, with Itraconazole (Group F)

End point title	Tmax of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants, with Itraconazole (Group F)[32]

End point description:

Time to maximum plasma concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[32] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group F - MK-3682 300 mg (tablet) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	8			
Units: hr				
median (full range (min-max))				
Day 1	2 (1 to 3)			
Day 7	1 (1 to 3)			

Statistical analyses

No statistical analyses for this end point

Primary: Observed Terminal Half-Life (t1/2) of MK-3682 after Single Dose of MK-

3682 as the Capsule Formulation in Healthy Participants (Group A)

End point title	Observed Terminal Half-Life (t1/2) of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Healthy Participants (Group A)[33]

End point description:

The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). All participants are fasted. Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[33] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 10 mg (Cohort 1a) - PK	Group A - MK-3682 25 mg (Cohort 2a) - PK	Group A - MK-3682 50 mg (Cohort 3a) - PK	Group A - MK-3682 150 mg (Cohort 4a) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	6	6	6
Units: hr				
geometric mean (geometric coefficient of variation)	0.839 (± 27.3)	0.872 (± 33.7)	0.979 (± 36.6)	1.05 (± 25)

End point values	Group A - MK-3682 300 mg (Cohort 5a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: hr				
geometric mean (geometric coefficient of variation)	1.13 (± 31.6)			

Statistical analyses

No statistical analyses for this end point

Primary: T1/2 of MK-3682 after Single Dose of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)

End point title	T1/2 of MK-3682 after Single Dose of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Fed State in Healthy Participants (Group A - Cohort 4a)[34]

End point description:

The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could

have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[34] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 150 mg (Fed) (Cohort 4a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: hr				
geometric mean (geometric coefficient of variation)	1.63 (± 31.9)			

Statistical analyses

No statistical analyses for this end point

Primary: T1/2 of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A – Cohort 6a)

End point title	T1/2 of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A – Cohort 6a)[35]

End point description:

The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[35] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 300 mg (Cohort 6a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: hr				
geometric mean (geometric coefficient of variation)	2.13 (± 85.4)			

Statistical analyses

No statistical analyses for this end point

Primary: T1/2 of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Genotype 1, HCV-infected Participants (Group B)

End point title	T1/2 of MK-3682 after Single Dose of MK-3682 as the Capsule Formulation in Genotype 1, HCV-infected Participants (Group B)[36]

End point description:

The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose. 99999 = Not Calculated.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[36] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group B - MK-3682 10 mg (Cohort 1b) - PK	Group B - MK-3682 25 mg (Cohort 2b) - PK	Group B - MK-3682 50 mg (Cohort 3b) - PK	Group B - MK-3682 150 mg (Cohort 4b) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3	3	3	2
Units: hr				
geometric mean (geometric coefficient of variation)	1.36 (± 52.7)	0.926 (± 34.5)	1.09 (± 32.5)	1.11 (± 99999)

End point values	Group B - MK-3682 300 mg (Cohort 5b) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	3			
Units: hr				
geometric mean (geometric coefficient of variation)	1.59 (± 1.7)			

Statistical analyses

No statistical analyses for this end point

Primary: T1/2 of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-infected Participants (Groups C and D)

End point title	T1/2 of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-infected Participants (Groups C and D)[37]

End point description:

The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[37] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Groups C and D - MK-3682 50 mg (capsule) - PK	Groups C and D - MK-3682 150 mg (capsule) - PK	Group C - MK-3682 250 mg (capsule) - PK	Groups C and D - MK-3682 300 mg (capsule) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	10	9	8	17
Units: hr				
geometric mean (geometric coefficient of variation)	1.04 (± 25.1)	1.11 (± 22.5)	1.21 (± 21.7)	1.54 (± 34)

End point values	Group C - MK-3682 400 mg (capsule) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	7			
Units: hr				
geometric mean (geometric coefficient of variation)	2.58 (± 40.3)			

Statistical analyses

No statistical analyses for this end point

Primary: T1/2 of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants (Group C)

End point title	T1/2 of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants (Group C)[38]

End point description:

The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[38] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group C - MK-3682 300 mg (tablet) - PK	Group C - MK-3682 450 mg (tablet) - PK		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	7	7		
Units: hr				
geometric mean (geometric coefficient of variation)	2.5 (± 55.9)	3.64 (± 54.8)		

Statistical analyses

No statistical analyses for this end point

Primary: T1/2 of MK-3682 after Single Dose of MK-3682 as Capsule Formulation in Genotype 1, HCV-infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)

End point title	T1/2 of MK-3682 after Single Dose of MK-3682 as Capsule Formulation in Genotype 1, HCV-infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)[39]

End point description:

The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose. 99999 = Not Calculated.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[39] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group E - MK-3682 150 mg (Cohort 1e) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	2			
Units: hr				

geometric mean (geometric coefficient of variation)	1.16 (± 99999)			

Statistical analyses

No statistical analyses for this end point

Primary: T1/2 of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)

End point title	T1/2 of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)[40]

End point description:

The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[40] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group E - MK-3682 300 mg (Cohort 2e) - PK	Group E - MK-3682 450 mg (Cohort 3e) - PK		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	3	7		
Units: hr				
geometric mean (geometric coefficient of variation)	1.18 (± 27.2)	2.38 (± 34.3)		

Statistical analyses

No statistical analyses for this end point

Primary: T1/2 of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants, with Itraconazole (Group F)

End point title	T1/2 of MK-3682 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-infected Participants, with Itraconazole (Group F)[41]

End point description:

The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-

3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[41] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group F - MK-3682 300 mg (tablet) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	8			
Units: hr				
geometric mean (geometric coefficient of variation)	4.3 (± 52.8)			

Statistical analyses

No statistical analyses for this end point

Primary: AUC0-inf of M6 after Single Dose of MK-3682 as the Capsule Formulation in Healthy Participants (Group A)

End point title	AUC0-inf of M6 after Single Dose of MK-3682 as the Capsule Formulation in Healthy Participants (Group A)[42]

End point description:

Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). All participants are fasted. Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[42] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 10 mg (Cohort 1a) - PK	Group A - MK-3682 25 mg (Cohort 2a) - PK	Group A - MK-3682 50 mg (Cohort 3a) - PK	Group A - MK-3682 150 mg (Cohort 4a) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	6	6	6
Units: h·umol/L				
geometric mean (geometric coefficient of variation)	1.68 (± 47.4)	5.01 (± 27.2)	8.77 (± 8.4)	19.8 (± 12.7)

End point values	Group A - MK-3682 300 mg (Cohort 5a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: h·umol/L				
geometric mean (geometric coefficient of variation)	29.7 (± 32.1)			

Statistical analyses

No statistical analyses for this end point

Primary: AUC0-inf of M6 after Single Dose of MK-3682 as the Capsule Formulation in Fed State in Healthy Participants (Group A – Cohort 4a)

End point title	AUC0-inf of M6 after Single Dose of MK-3682 as the Capsule Formulation in Fed State in Healthy Participants (Group A – Cohort 4a)[43]

End point description:

Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[43] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 150 mg (Fed) (Cohort 4a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: h·umol/L				
geometric mean (geometric coefficient of variation)	17.9 (± 13.4)			

Statistical analyses

No statistical analyses for this end point

Primary: AUC0-inf of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A – Cohort 6a)

End point title	AUC0-inf of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A – Cohort 6a)[44]

End point description:

Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[44] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 300 mg (Cohort 6a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: h·umol/L				
geometric mean (geometric coefficient of variation)				
Day 1	15.1 (± 16.5)			
Day 7	20.6 (± 17.9)			

Statistical analyses

No statistical analyses for this end point

Primary: AUC0-inf of M6 after Single Dose of MK-3682 as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)

End point title	AUC0-inf of M6 after Single Dose of MK-3682 as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)[45]

End point description:

Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose. 99999 = Not Calculated.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[45] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group B - MK-3682 10 mg (Cohort 1b) - PK	Group B - MK-3682 25 mg (Cohort 2b) - PK	Group B - MK-3682 50 mg (Cohort 3b) - PK	Group B - MK-3682 150 mg (Cohort 4b) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3	3	3	2
Units: h·umol/L				
geometric mean (geometric coefficient of variation)	2.26 (± 22.3)	5.78 (± 4.7)	7.31 (± 11.1)	17.5 (± 99999)

End point values	Group B - MK-3682 300 mg (Cohort 5b) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	3			
Units: h·umol/L				
geometric mean (geometric coefficient of variation)	33.4 (± 37)			

Statistical analyses

No statistical analyses for this end point

Primary: AUC0-inf of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)

End point title	AUC0-inf of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)[46]

End point description:

Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[46] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Groups C and D - MK-3682 50 mg (capsule) - PK	Groups C and D - MK-3682 150 mg (capsule) - PK	Group C - MK-3682 250 mg (capsule) - PK	Groups C and D - MK-3682 300 mg (capsule) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	10	9	8	17
Units: h·umol/L				
geometric mean (geometric coefficient of variation)				
Day 1	4.74 (± 37.6)	8.94 (± 20.2)	14.6 (± 24.3)	14.4 (± 20.8)
Day 7	7.12 (± 37.6)	12.2 (± 18.9)	19.2 (± 23.1)	19 (± 16.3)

End point values	Group C - MK-3682 400 mg (capsule) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	7			
Units: h·umol/L				
geometric mean (geometric coefficient of variation)				
Day 1	19.4 (± 11.1)			
Day 7	24.4 (± 7.2)			

Statistical analyses

No statistical analyses for this end point

Primary: AUC0-inf of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)

End point title	AUC0-inf of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)[47]

End point description:

Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[47] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group C - MK-3682 300 mg (tablet) - PK	Group C - MK-3682 450 mg (tablet) - PK		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	7	7		
Units: h·umol/L				
geometric mean (geometric coefficient of variation)				
Day 1	14.7 (± 36.6)	16.1 (± 23.5)		
Day 7	21.4 (± 26.7)	24.7 (± 22.5)		

Statistical analyses

No statistical analyses for this end point

Primary: AUC0-inf of M6 after Single Dose of MK-3682 as Capsule Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)

End point title	AUC0-inf of M6 after Single Dose of MK-3682 as Capsule Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)[48]

End point description:

Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose. 99999 = Not Calculated.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[48] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group E - MK-3682 150 mg (Cohort 1e) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	2			
Units: h·umol/L				
geometric mean (geometric coefficient of variation)	16.4 (± 99999)			

Statistical analyses

No statistical analyses for this end point

Primary: AUC0-inf of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as

Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)

End point title	AUC0-inf of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)[49]

End point description:

Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[49] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group E - MK-3682 300 mg (Cohort 2e) - PK	Group E - MK-3682 450 mg (Cohort 3e) - PK		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	3	7		
Units: h·umol/L				
geometric mean (geometric coefficient of variation)				
Day 1	13.4 (± 22.3)	18.4 (± 17)		
Day 7	17.5 (± 23.5)	26.1 (± 26.5)		

Statistical analyses

No statistical analyses for this end point

Primary: AUC0-inf of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, with Intraconazole (Group F)

End point title	AUC0-inf of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, with Intraconazole (Group F)[50]

End point description:

Area under the drug concentration-time curve from time zero to infinity estimated as AUC0-t + Cest/λz, where λz is the terminal elimination rate constant, calculated for the first dose only. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[50] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group F - MK-3682 300 mg (tablet) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	8			
Units: h·umol/L				
geometric mean (geometric coefficient of variation)				
Day 1	13.2 (± 32)			
Day 7	23.8 (± 37)			

Statistical analyses

No statistical analyses for this end point

Primary: Cmax of M6 after Single Dose of MK-3682 as the Capsule Formulation in Healthy Participants (Group A)

End point title	Cmax of M6 after Single Dose of MK-3682 as the Capsule Formulation in Healthy Participants (Group A)[51]

End point description:

Maximum observed plasma drug concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). All participants are fasted. Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[51] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 10 mg (Cohort 1a) - PK	Group A - MK-3682 25 mg (Cohort 2a) - PK	Group A - MK-3682 50 mg (Cohort 3a) - PK	Group A - MK-3682 150 mg (Cohort 4a) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	6	6	6
Units: nmol/L				
geometric mean (geometric coefficient of variation)	63.2 (± 19.8)	146 (± 13.6)	283 (± 14.7)	758 (± 28.2)

End point values	Group A - MK-3682 300 mg (Cohort 5a) - PK			

Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: nmol/L				
geometric mean (geometric coefficient of variation)	1190 (± 16.6)			

Statistical analyses

No statistical analyses for this end point

Primary: Cmax of M6 after Single Dose of MK-3682 as the Capsule Formulation in Fed State in Healthy Participants (Group A – Cohort 4a)

End point title	Cmax of M6 after Single Dose of MK-3682 as the Capsule Formulation in Fed State in Healthy Participants (Group A – Cohort 4a)[52]

End point description:

Maximum observed plasma drug concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[52] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 150 mg (Fed) (Cohort 4a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: nmol/L				
geometric mean (geometric coefficient of variation)	509 (± 8.4)			

Statistical analyses

No statistical analyses for this end point

Primary: Cmax of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A – Cohort 6a)

End point title	Cmax of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A – Cohort 6a)[53]

End point description:

Maximum observed plasma drug concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis).

Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[53] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 300 mg (Cohort 6a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: nmol/L				
geometric mean (geometric coefficient of variation)				
Day 1	1310 (± 7.5)			
Day 7	1630 (± 14.9)			

Statistical analyses

No statistical analyses for this end point

Primary: Cmax of M6 after Single Dose of MK-3682 as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)

End point title	Cmax of M6 after Single Dose of MK-3682 as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)[54]

End point description:

Maximum observed plasma drug concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose. 99999 = Not Calculated.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[54] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group B - MK-3682 10 mg (Cohort 1b) - PK	Group B - MK-3682 25 mg (Cohort 2b) - PK	Group B - MK-3682 50 mg (Cohort 3b) - PK	Group B - MK-3682 150 mg (Cohort 4b) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3	3	3	2
Units: nmol/L				
geometric mean (geometric coefficient of variation)	55 (± 15)	170 (± 7.2)	279 (± 5.2)	710 (± 99999)

End point values	Group B - MK-3682 300 mg (Cohort 5b) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	3			
Units: nmol/L				
geometric mean (geometric coefficient of variation)	1210 (± 33.8)			

Statistical analyses

No statistical analyses for this end point

Primary: Cmax of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)

End point title	Cmax of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)[55]

End point description:

Maximum observed plasma drug concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[55] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Groups C and D - MK-3682 50 mg (capsule) - PK	Groups C and D - MK-3682 150 mg (capsule) - PK	Group C - MK-3682 250 mg (capsule) - PK	Groups C and D - MK-3682 300 mg (capsule) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	10	9	8	17
Units: nmol/L				
geometric mean (geometric coefficient of variation)				
Day 1	298 (± 34.2)	641 (± 7.6)	1200 (± 20)	1130 (± 22.7)
Day 7	471 (± 33.7)	931 (± 14.4)	1460 (± 21.9)	1420 (± 15.3)

End point values	Group C - MK-			

	3682 400 mg (capsule) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	7			
Units: nmol/L				
geometric mean (geometric coefficient of variation)				
Day 1	1560 (± 18.9)			
Day 7	1760 (± 10.4)			

Statistical analyses

No statistical analyses for this end point

Primary: Cmax of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)

End point title	Cmax of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)[56]

End point description:

Maximum observed plasma drug concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[56] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group C - MK-3682 300 mg (tablet) - PK	Group C - MK-3682 450 mg (tablet) - PK		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	7	7		
Units: nmol/L				
geometric mean (geometric coefficient of variation)				
Day 1	1010 (± 31.5)	1210 (± 21.9)		
Day 7	1420 (± 23.2)	1680 (± 21.5)		

Statistical analyses

No statistical analyses for this end point

Primary: Cmax of M6 after Single Dose of MK-3682 as Capsule Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child

Pugh Class A) (Group E - Cohort 1e)

End point title	Cmax of M6 after Single Dose of MK-3682 as Capsule Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)[57]

End point description:

Maximum observed plasma drug concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose. 99999 = Not Calculated.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[57] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group E - MK-3682 150 mg (Cohort 1e) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	2			
Units: nmol/L				
geometric mean (geometric coefficient of variation)	597 (± 99999)			

Statistical analyses

No statistical analyses for this end point

Primary: Cmax of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)

End point title	Cmax of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)[58]

End point description:

Maximum observed plasma drug concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[58] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group E - MK-3682 300 mg (Cohort 2e) - PK	Group E - MK-3682 450 mg (Cohort 3e) - PK		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	3	7		
Units: nmol/L				
geometric mean (geometric coefficient of variation)				
Day 1	1100 (± 11.5)	1180 (± 11.9)		
Day 7	1550 (± 11.4)	1740 (± 19.7)		

Statistical analyses

No statistical analyses for this end point

Primary: Cmax of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, with Intraconazole (Group F)

End point title	Cmax of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, with Intraconazole (Group F)[59]

End point description:

Maximum observed plasma drug concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[59] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group F - MK-3682 300 mg (tablet) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	8			
Units: nmol/L				
geometric mean (geometric coefficient of variation)				
Day 1	738 (± 31.7)			
Day 7	1180 (± 33.2)			

Statistical analyses

No statistical analyses for this end point

Primary: Tmax of M6 after Single Dose of MK-3682 as the Capsule Formulation in Healthy Participants (Group A)

End point title	Tmax of M6 after Single Dose of MK-3682 as the Capsule Formulation in Healthy Participants (Group A)[60]

End point description:

Time to maximum plasma concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). All participants are fasted. Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[60] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 10 mg (Cohort 1a) - PK	Group A - MK-3682 25 mg (Cohort 2a) - PK	Group A - MK-3682 50 mg (Cohort 3a) - PK	Group A - MK-3682 150 mg (Cohort 4a) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	6	6	6
Units: hr				
median (full range (min-max))	3.01 (2 to 6)	3.5 (2 to 4.05)	4 (2 to 6)	2.53 (2 to 6.05)

End point values	Group A - MK-3682 300 mg (Cohort 5a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: hr				
median (full range (min-max))	3.5 (3 to 4)			

Statistical analyses

No statistical analyses for this end point

Primary: Tmax of M6 after Single Dose of MK-3682 as the Capsule Formulation in Fed State in Healthy Participants (Group A – Cohort 4a)

End point title	Tmax of M6 after Single Dose of MK-3682 as the Capsule Formulation in Fed State in Healthy Participants (Group A – Cohort 4a)[61]

End point description:

Time to maximum plasma concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[61] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 150 mg (Fed) (Cohort 4a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: hr				
median (full range (min-max))	6 (6 to 8)			

Statistical analyses

No statistical analyses for this end point

Primary: Tmax of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A – Cohort 6a)

End point title	Tmax of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A – Cohort 6a)[62]

End point description:

Time to maximum plasma concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[62] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 300 mg (Cohort 6a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: hr				
median (full range (min-max))				
Day 1	3 (2 to 3.05)			
Day 7	2.5 (1 to 4)			

Statistical analyses

No statistical analyses for this end point

Primary: Tmax of M6 after Single Dose of MK-3682 as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)

End point title	Tmax of M6 after Single Dose of MK-3682 as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)[63]

End point description:

Time to maximum plasma concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[63] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group B - MK-3682 10 mg (Cohort 1b) - PK	Group B - MK-3682 25 mg (Cohort 2b) - PK	Group B - MK-3682 50 mg (Cohort 3b) - PK	Group B - MK-3682 150 mg (Cohort 4b) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3	3	3	2
Units: hr				
median (full range (min-max))	4 (4 to 6)	4 (3.03 to 4)	2.05 (2 to 4)	3.52 (3.03 to 4)

End point values	Group B - MK-3682 300 mg (Cohort 5b) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	3			
Units: hr				
median (full range (min-max))	4 (1 to 6)			

Statistical analyses

No statistical analyses for this end point

Primary: Tmax of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)

End point title	Tmax of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)[64]

End point description:

Time to maximum plasma concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[64] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Groups C and D - MK-3682 50 mg (capsule) - PK	Groups C and D - MK-3682 150 mg (capsule) - PK	Group C - MK-3682 250 mg (capsule) - PK	Groups C and D - MK-3682 300 mg (capsule) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	10	9	8	17
Units: hr				
median (full range (min-max))				
Day 1	4 (1 to 8)	3 (0.98 to 4)	3.5 (2 to 4)	3 (2 to 6)
Day 7	2 (1.92 to 6)	2 (1 to 3)	3.5 (3 to 4)	3 (1 to 4)

End point values	Group C - MK-3682 400 mg (capsule) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	7			
Units: hr				
median (full range (min-max))				
Day 1	4 (3 to 6)			
Day 7	4 (2 to 4)			

Statistical analyses

No statistical analyses for this end point

Primary: Tmax of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)

End point title	Tmax of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)[65]

End point description:

Time to maximum plasma concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[65] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group C - MK-3682 300 mg (tablet) - PK	Group C - MK-3682 450 mg (tablet) - PK		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	7	7		
Units: hr				
median (full range (min-max))				
Day 1	4 (2 to 6)	4 (3 to 6.03)		
Day 7	4 (2 to 4)	4 (3 to 6)		

Statistical analyses

No statistical analyses for this end point

Primary: Tmax of M6 after Single Dose of MK-3682 as Capsule Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)

End point title	Tmax of M6 after Single Dose of MK-3682 as Capsule Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)[66]

End point description:

Time to maximum plasma concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[66] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group E - MK-3682 150 mg (Cohort 1e) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	2			
Units: hr				
median (full range (min-max))	4 (4 to 4)			

Statistical analyses

No statistical analyses for this end point

Primary: Tmax of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1,HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)

End point title	Tmax of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1,HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)[67]

End point description:

Time to maximum plasma concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[67] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group E - MK-3682 300 mg (Cohort 2e) - PK	Group E - MK-3682 450 mg (Cohort 3e) - PK		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	3	7		
Units: hr				
median (full range (min-max))				
Day 1	3 (2 to 4)	4 (3 to 4)		
Day 7	2 (2 to 4)	4 (2 to 4)		

Statistical analyses

No statistical analyses for this end point

Primary: Tmax of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the

Tablet Formulation in Genotype 1, HCV-Infected Participants, with Intraconazole (Group F)

End point title	Tmax of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, with Intraconazole (Group F)[68]

End point description:

Time to maximum plasma concentration was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken Day 1: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 1 dose; Day 7: prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post Day 7 dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[68] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group F - MK-3682 300 mg (tablet) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	8			
Units: hr				
median (full range (min-max))				
Day 1	10 (6 to 23.5)			
Day 7	4 (3 to 8)			

Statistical analyses

No statistical analyses for this end point

Primary: T1/2 of M6 after Single Dose of MK-3682 as the Capsule Formulation in Healthy Participants (Group A)

End point title	T1/2 of M6 after Single Dose of MK-3682 as the Capsule Formulation in Healthy Participants (Group A)[69]

End point description:

The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). All participants are fasted. Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[69] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 10 mg (Cohort 1a) - PK	Group A - MK-3682 25 mg (Cohort 2a) - PK	Group A - MK-3682 50 mg (Cohort 3a) - PK	Group A - MK-3682 150 mg (Cohort 4a) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	6	6	6
Units: hr				
geometric mean (geometric coefficient of variation)	22.5 (± 6.2)	24.6 (± 12.8)	22.9 (± 14)	29.1 (± 15.5)

End point values	Group A - MK-3682 300 mg (Cohort 5a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: hr				
geometric mean (geometric coefficient of variation)	28.8 (± 14.2)			

Statistical analyses

No statistical analyses for this end point

Primary: T1/2 of M6 after Single Dose of MK-3682 as the Capsule Formulation in Fed State in Healthy Participants (Group A – Cohort 4a)

End point title	T1/2 of M6 after Single Dose of MK-3682 as the Capsule Formulation in Fed State in Healthy Participants (Group A – Cohort 4a)[70]

End point description:

The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[70] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 150 mg (Fed) (Cohort 4a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: hr				
geometric mean (geometric coefficient of variation)	27.1 (± 9.1)			

Statistical analyses

No statistical analyses for this end point

Primary: T1/2 of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A – Cohort 6a)

End point title	T1/2 of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Healthy Participants (Group A – Cohort 6a)[71]

End point description:

The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[71] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 300 mg (Cohort 6a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: hr				
geometric mean (geometric coefficient of variation)	32.2 (± 10.3)			

Statistical analyses

No statistical analyses for this end point

Primary: T1/2 of M6 after Single Dose of MK-3682 as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)

End point title	T1/2 of M6 after Single Dose of MK-3682 as the Capsule Formulation in Genotype 1, HCV-Infected Participants (Group B)[72]

End point description:

The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose. 99999 = Not Calculated.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[72] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group B - MK-3682 10 mg (Cohort 1b) - PK	Group B - MK-3682 25 mg (Cohort 2b) - PK	Group B - MK-3682 50 mg (Cohort 3b) - PK	Group B - MK-3682 150 mg (Cohort 4b) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3	3	3	2
Units: hr				
geometric mean (geometric coefficient of variation)	20.1 (± 3.4)	21.2 (± 4.8)	21.7 (± 19.8)	26.9 (± 99999)

End point values	Group B - MK-3682 300 mg (Cohort 5b) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	3			
Units: hr				
geometric mean (geometric coefficient of variation)	28 (± 12.1)			

Statistical analyses

No statistical analyses for this end point

Primary: T1/2 of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)

End point title	T1/2 of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Capsule Formulation in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)[73]

End point description:

The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[73] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Groups C and D - MK-3682 50 mg (capsule) - PK	Groups C and D - MK-3682 150 mg (capsule) - PK	Group C - MK-3682 250 mg (capsule) - PK	Groups C and D - MK-3682 300 mg (capsule) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	10	9	8	17
Units: hr				
geometric mean (geometric coefficient of variation)	25.5 (± 16.8)	28.9 (± 15.2)	30.2 (± 12.3)	32.6 (± 12.7)

End point values	Group C - MK-3682 400 mg (capsule) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	7			
Units: hr				
geometric mean (geometric coefficient of variation)	35.8 (± 17.8)			

Statistical analyses

No statistical analyses for this end point

Primary: T1/2 of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)

End point title	T1/2 of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants (Group C)[74]

End point description:

The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[74] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group C - MK-3682 300 mg (tablet) - PK	Group C - MK-3682 450 mg (tablet) - PK		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	7	7		
Units: hr				
geometric mean (geometric coefficient of variation)	32.4 (± 7.7)	30.8 (± 26.8)		

Statistical analyses

No statistical analyses for this end point

Primary: T1/2 of M6 after Single Dose of MK-3682 as Capsule Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)

End point title	T1/2 of M6 after Single Dose of MK-3682 as Capsule Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 1e)[75]

End point description:

The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose. 99999 = Not Calculated.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[75] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group E - MK-3682 150 mg (Cohort 1e) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	2			
Units: hr				
geometric mean (geometric coefficient of variation)	24 (± 99999)			

Statistical analyses

No statistical analyses for this end point

Primary: T1/2 of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)

End point title	T1/2 of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as Capsule or Tablet Formulation in Genotype 1, HCV-Infected Participants with Mildly Impaired Hepatic Function (Child Pugh Class A) (Group E - Cohort 2e and Cohort 3e)[76]

End point description:

The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. PK

Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[76] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group E - MK-3682 300 mg (Cohort 2e) - PK	Group E - MK-3682 450 mg (Cohort 3e) - PK		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	3	7		
Units: hr				
geometric mean (geometric coefficient of variation)	27.5 (± 9.3)	26.2 (± 24.8)		

Statistical analyses

No statistical analyses for this end point

Primary: T1/2 of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, with Intraconazole (Group F)

End point title	T1/2 of M6 after Multiple Doses of MK-3682 Once-Daily x 7 Days as the Tablet Formulation in Genotype 1, HCV-Infected Participants, with Intraconazole (Group F)[77]

End point description:

The time measured for the plasma concentration to decrease by one half (t1/2) was obtained. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). Measurements were taken prior to dosing, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, 36, 48, 72, 96, and 120 hours post dose.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 7 dose

Notes:

[77] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group F - MK-3682 300 mg (tablet) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	8			
Units: hr				
geometric mean (geometric coefficient of variation)	38.9 (± 17.7)			

Statistical analyses

No statistical analyses for this end point

Primary: Cumulative Urine Excretion of Unchanged MK-3682 in Healthy Participants (Group A)

End point title	Cumulative Urine Excretion of Unchanged MK-3682 in Healthy Participants (Group A)[78]

End point description:

Cumulative urine excretion of unchanged MK-3682 in healthy participants was obtained. Urine PK samples were taken on Day 1 prior to dosing (-2 to 0 h), 0-4, 4-8, 8-12, 12-24, 24-48, 48-72, 72-96, and 96-120 h intervals post dose. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). All participants are fasted.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[78] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 10 mg (Cohort 1a) - PK	Group A - MK-3682 25 mg (Cohort 2a) - PK	Group A - MK-3682 50 mg (Cohort 3a) - PK	Group A - MK-3682 150 mg (Cohort 4a) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	6	6	6
Units: umol				
arithmetic mean (standard deviation)	0.28 (± 0.08)	0.586 (± 0.164)	1.56 (± 0.397)	7.73 (± 4.67)

End point values	Group A - MK-3682 300 mg (Cohort 5a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: umol				
arithmetic mean (standard deviation)	13.1 (± 4.16)			

Statistical analyses

No statistical analyses for this end point

Primary: Cumulative Urine Excretion of Unchanged M6 in Healthy Participants (Group A)

End point title	Cumulative Urine Excretion of Unchanged M6 in Healthy Participants (Group A)[79]

End point description:

Cumulative urine excretion of unchanged M6 in healthy participants was obtained. Urine PK samples were taken on Day 1 prior to dosing (-2 to 0 h), 0-4, 4-8, 8-12, 12-24, 24-48, 48-72, 72-96, and 96-120 h intervals post dose. PK Population: a subpopulation of the per-protocol population, selecting all participants exposed to MK-3682 who had available and evaluable data (e.g., excluding deviations and/or other events that could have an impact on the PK analysis). All participants are fasted.

End point type	Primary

End point timeframe:

Up to 120 hours post Day 1 dose

Notes:

[79] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group A - MK-3682 10 mg (Cohort 1a) - PK	Group A - MK-3682 25 mg (Cohort 2a) - PK	Group A - MK-3682 50 mg (Cohort 3a) - PK	Group A - MK-3682 150 mg (Cohort 4a) - PK
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	6	6	6	6
Units: umol				
arithmetic mean (standard deviation)	5.93 (± 1.42)	15.2 (± 2.5)	31.8 (± 5.69)	101 (± 6.86)

End point values	Group A - MK-3682 300 mg (Cohort 5a) - PK			
Subject group type	Subject analysis set			
Number of subjects analysed	6			
Units: umol				
arithmetic mean (standard deviation)	200 (± 37.9)			

Statistical analyses

No statistical analyses for this end point

Primary: Reduction in Hepatitis C Virus (HCV) RNA from Baseline on Day 8 Following MK-3682 50-450 mg for 7 Days in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)

End point title	Reduction in Hepatitis C Virus (HCV) RNA from Baseline on Day 8 Following MK-3682 50-450 mg for 7 Days in Genotype 1, 2 and 3, HCV-Infected Participants (Groups C and D)[80]

End point description:

Reduction in HCV RNA from baseline on Day 8 following MK-3682 50-450 mg for 7 Days in Genotype 1, 2 and 3, HCV-infected participants was obtained. Per-Protocol Population: participants who complied

with the protocol sufficiently to ensure that these data were likely to exhibit the effects of treatment, according to the underlying scientific model.

End point type	Primary

End point timeframe:

Baseline and Day 8

Notes:

[80] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Groups C and D - Placebo (pooled) - PP	Groups C and D - MK-3682 50 mg (capsule) - PP	Groups C and D - MK-3682 150 mg (capsule) - PP	Group C - MK-3682 250 mg (capsule) - PP
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	8	10	9	8
Units: log10 IU/mL				
arithmetic mean (standard deviation)	0.16 (± 0.183)	0.65 (± 0.575)	2.43 (± 0.78)	3.86 (± 0.822)

End point values	Groups C and D - MK-3682 300 mg (capsule) - PP	Group C - MK-3682 400 mg (capsule) - PP	Group C - MK-3682 300 mg (tablet) - PP	Group C - MK-3682 450 mg (tablet) - PP
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	17	7	7	7
Units: log10 IU/mL				
arithmetic mean (standard deviation)	4.07 (± 0.563)	4.33 (± 0.349)	3.3 (± 0.68)	4.33 (± 0.574)

Statistical analyses

No statistical analyses for this end point

Primary: Maximum Reduction in log10 HCV RNA from Baseline - Normal Participants (from Groups B and C) vs. Mild Hepatic Impairment Participants (Group E)

End point title	Maximum Reduction in log10 HCV RNA from Baseline - Normal Participants (from Groups B and C) vs. Mild Hepatic Impairment Participants (Group E)[81]

End point description:

Maximum reduction in log10 HCV RNA from baseline in normal (non-hepatic impaired) participants vs. participants with mild hepatic impairment was obtained. Per-Protocol Population: participants who complied with the protocol sufficiently to ensure that these data were likely to exhibit the effects of treatment, according to the underlying scientific model. 99999 = Not Applicable.

End point type	Primary

End point timeframe:

Baseline and 28 days after last dose of study drug

Notes:

[81] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Statistical analyses were neither planned nor performed for this endpoint.

End point values	Group B - MK-3682 300 mg (Cohort 4b) - PP	Group C - MK-3682 300 mg (capsule) - PP	Group C - MK-3682 450 mg (tablet) - PP	Group E - MK-3682 150 mg (Cohort 1e) - PP
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	2	8	7	2
Units: log10 IU/mL				
arithmetic mean (standard deviation)				
Genotype 1 (pooled 1a + 1b); N=2, 8, 7, 2, 3, 7.	1.15 (± 0.274)	4.19 (± 0.754)	4.5 (± 0.644)	1.36 (± 0.774)
Genotype 1a; N=1, 3, 2, 0, 2, 1.	0.96 (± 99999)	4.82 (± 0.504)	5.06 (± 0.489)	99999 (± 99999)
Genotype 1b; N=1, 5, 5, 2, 1, 6.	1.35 (± 99999)	3.82 (± 0.636)	4.28 (± 0.584)	1.36 (± 0.774)

End point values	Group E - MK-3682 300 mg (Cohort 2e) - PP	Group E - MK-3682 450 mg (Cohort 3e) - PP		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	3	7		
Units: log10 IU/mL				
arithmetic mean (standard deviation)				
Genotype 1 (pooled 1a + 1b); N=2, 8, 7, 2, 3, 7.	3.15 (± 0.42)	3.16 (± 0.989)		
Genotype 1a; N=1, 3, 2, 0, 2, 1.	2.92 (± 0.239)	3.6 (± 99999)		
Genotype 1b; N=1, 5, 5, 2, 1, 6.	3.59 (± 99999)	3.08 (± 1.06)		

Statistical analyses

No statistical analyses for this end point

Adverse events information

Timeframe for reporting adverse events:

Up to 42 days (28 days after last study drug administration)

Adverse event reporting additional description:

APaT Population: includes all participants who received at least one dose of the study drug. For Cohort 4a, SAEs and NSAEs are given for participants on the fasted regimen.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	16.1

Reporting groups

Reporting group title	Group A - MK-3682 25 mg (Cohort 2a)

Reporting group description:

Participants were administered a single dose of MK-3682 25 mg as oral capsules under fasted conditions.

Reporting group title	Group A - MK-3682 10 mg (Cohort 1a)

Reporting group description:

Participants were administered a single dose of MK-3682 10 mg as oral capsules under fasted conditions.

Reporting group title	Group A - Placebo (Cohort 1a -Cohort 5a - pooled)

Reporting group description:

Participants were administered a single dose of MK-3682-matching placebo as oral capsules under fasted conditions (Cohorts 1a, 2a, 3a, 5a); Participants were administered single doses of MK-3682-matching placebo as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods (Cohort 4a).

Reporting group title	Group A - MK-3682 50 mg (Cohort 3a)

Reporting group description:

Participants were administered a single dose of MK-3682 50 mg as oral capsules under fasted conditions.

Reporting group title	Group A - MK-3682 150 mg (Cohort 4a)

Reporting group description:

Participants were administered single doses of MK-3682 150 mg as oral capsules on Days 1 and 7 in a 2-period crossover design (fasted/fed) with a 6 day washout between dosing periods.

Reporting group title	Group A - MK-3682 300 mg (Cohort 5a)

Reporting group description:

Participants were administered a single dose of MK-3682 300 mg as oral capsules under fasted conditions.

Reporting group title	Group A - Placebo (Cohort 6a)

Reporting group description:

Participants were administered single doses of MK-3682-matching placebo as oral capsules for 7 days under fasted conditions.

Reporting group title	Group A - MK-3682 300 mg (Cohort 6a)

Reporting group description:

Participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Group B - MK-3682 10 mg (Cohort 1b)

Reporting group description:

Participants were administered a single dose of MK-3682 10 mg as oral capsules under fasted conditions.

Reporting group title	Group B - MK-3682 150 mg (Cohort 4b)

Reporting group description:

Participants were administered a single dose of MK-3682 150 mg as oral capsules under fasted

conditions.

Reporting group title	Group B - MK-3682 50 mg (Cohort 3b)

Reporting group description:

Participants were administered a single dose of MK-3682 50 mg oral capsules under fasted conditions.

Reporting group title	Group B - MK-3682 25 mg (Cohort 2b)

Reporting group description:

Participants were administered a single dose of MK-3682 25 mg as oral capsules under fasted conditions.

Reporting group title	Group B - MK-3682 300 mg (Cohort 5b)

Reporting group description:

Participants were administered a single dose of MK-3682 300 mg oral capsules under fasted conditions.

Reporting group title	Groups C and D - MK-3682 50 mg (capsule)

Reporting group description:

Participants were administered single doses of MK-3682 50 mg as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Groups C and D - MK-3682 150 mg (capsule)

Reporting group description:

Participants were administered single doses of MK-3682 150 mg as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Group C - MK-3682 250 mg (capsule)

Reporting group description:

Participants were administered single doses of MK-3682 250 mg as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Groups C and D - MK-3682 300 mg (capsule)

Reporting group description:

Participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Group C - MK-3682 400 mg (capsule)

Reporting group description:

Participants were administered single doses of MK-3682 400 mg as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Group C - MK-3682 300 mg (tablet)

Reporting group description:

Participants were administered single doses of MK-3682 300 mg as oral tablets once daily for 7 days under fasted conditions.

Reporting group title	Groups C and D - Placebo (pooled)

Reporting group description:

Participants administered single doses of MK-3682-matching placebo as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Group C - MK-3682 450 mg (tablet)

Reporting group description:

Participants were administered single doses of MK-3682 450 mg as oral tablets once daily for 7 days under fasted conditions.

Reporting group title	Group E - MK-3682 150 mg (Cohort 1e)

Reporting group description:

Participants were administered a single dose of MK-3682 150 mg as oral capsules under fasted conditions.

Reporting group title	Group E - MK-3682 450 mg (Cohort 3e)

Reporting group description:

Participants were administered single doses of MK-3682 450 mg as oral tablets once daily for 7 days under fasted conditions.

Reporting group title	Group E - MK-3682 300 mg (Cohort 2e)

Reporting group description:

Participants were administered single doses of MK-3682 300 mg as oral capsules once daily for 7 days under fasted conditions.

Reporting group title	Group F - MK-3682 300 mg (tablet)

Reporting group description:

Participants were administered single doses of MK-3682 300 mg as oral tablets once daily for 7 days under fasted conditions. Participants were also administered Itraconazole 200 mg twice daily on Day -5 and 200 mg once daily from Day -4 to Day 11.

Serious adverse events	Group A - MK-3682 25 mg (Cohort 2a)	Group A - MK-3682 10 mg (Cohort 1a)	Group A - Placebo (Cohort 1a -Cohort 5a - pooled)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Serious adverse events	Group A - MK-3682 50 mg (Cohort 3a)	Group A - MK-3682 150 mg (Cohort 4a)	Group A - MK-3682 300 mg (Cohort 5a)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Serious adverse events	Group A - Placebo (Cohort 6a)	Group A - MK-3682 300 mg (Cohort 6a)	Group B - MK-3682 10 mg (Cohort 1b)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Serious adverse events	Group B - MK-3682 150 mg (Cohort 4b)	Group B - MK-3682 50 mg (Cohort 3b)	Group B - MK-3682 25 mg (Cohort 2b)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Serious adverse events	Group B - MK-3682 300 mg (Cohort 5b)	Groups C and D - MK-3682 50 mg (capsule)	Groups C and D - MK-3682 150 mg (capsule)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from	0	0	0

adverse events

Serious adverse events	Group C - MK-3682 250 mg (capsule)	Groups C and D - MK-3682 300 mg (capsule)	Group C - MK-3682 400 mg (capsule)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Serious adverse events	Group C - MK-3682 300 mg (tablet)	Groups C and D - Placebo (pooled)	Group C - MK-3682 450 mg (tablet)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Serious adverse events	Group E - MK-3682 150 mg (Cohort 1e)	Group E - MK-3682 450 mg (Cohort 3e)	Group E - MK-3682 300 mg (Cohort 2e)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Serious adverse events	Group F - MK-3682 300 mg (tablet)		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 8 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Group A - MK-3682 25 mg (Cohort 2a)	Group A - MK-3682 10 mg (Cohort 1a)	Group A - Placebo (Cohort 1a -Cohort 5a - pooled)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 6 (33.33%)	0 / 6 (0.00%)	5 / 10 (50.00%)

Vascular disorders			
Flushing			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Chest discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Feeling cold			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site anaesthesia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site bruise			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site haematoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 10 (20.00%)
occurrences (all)	0	0	2
Vessel puncture site reaction			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Breast enlargement			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Menstruation delayed			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Claustrophobia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Investigations			
Amylase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Lipase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pancreatic enzymes increased			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Procedural nausea			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dizziness postural			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Head discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

Headache			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Hypoaesthesia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Sensory loss			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Sinus headache			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Tinnitus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Ocular hyperaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Visual acuity reduced			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Abdominal pain lower			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Abnormal faeces			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Diarrhoea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Dyspepsia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Eructation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Faeces hard			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

Gastritis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Paraesthesia oral			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dermatosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Erythema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pruritus generalised			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rash			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Skin odour abnormal			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Skin reaction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Muscle tightness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Myalgia			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vulvitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Group A - MK-3682 50 mg (Cohort 3a)	Group A - MK-3682 150 mg (Cohort 4a)	Group A - MK-3682 300 mg (Cohort 5a)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 6 (33.33%)	4 / 6 (66.67%)	3 / 6 (50.00%)
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Hot flush			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Chest discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Fatigue			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Feeling cold			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site anaesthesia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site bruise			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	2
Vessel puncture site haematoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site reaction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Breast enlargement			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Menstruation delayed			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Epistaxis			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Claustrophobia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Investigations			
Amylase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lipase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pancreatic enzymes increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Procedural nausea			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 6 (16.67%)	2 / 6 (33.33%)	1 / 6 (16.67%)
occurrences (all)	1	2	1
Dizziness postural			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Head discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	1 / 6 (16.67%)
occurrences (all)	1	1	1
Hypoaesthesia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Sensory loss			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Sinus headache			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Somnolence			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Tinnitus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Ocular hyperaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Visual acuity reduced			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	1	1	0
Abdominal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Abdominal pain lower			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Abnormal faeces			

subjects affected / exposed	0 / 6 (0.00%)	2 / 6 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Constipation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Dyspepsia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eructation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Faeces hard			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 6 (0.00%)	2 / 6 (33.33%)	1 / 6 (16.67%)
occurrences (all)	0	2	1
Paraesthesia oral			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vomiting			

subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dermatosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Pruritus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pruritus generalised			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin odour abnormal			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin reaction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Muscle tightness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Myalgia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vulvitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Group A - Placebo (Cohort 6a)	Group A - MK-3682 300 mg (Cohort 6a)	Group B - MK-3682 10 mg (Cohort 1b)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 2 (50.00%)	2 / 6 (33.33%)	1 / 3 (33.33%)
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Chest discomfort			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Feeling cold			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site anaesthesia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site bruise			

subjects affected / exposed	0 / 2 (0.00%)	1 / 6 (16.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Vessel puncture site haematoma			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site reaction			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Breast enlargement			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Menstruation delayed			
subjects affected / exposed	0 / 2 (0.00%)	1 / 6 (16.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			

Claustrophobia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Investigations			
Amylase increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lipase increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pancreatic enzymes increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Procedural nausea			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 2 (0.00%)	1 / 6 (16.67%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Nervous system disorders			
Dizziness			

subjects affected / exposed	1 / 2 (50.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	2	0	0
Dizziness postural			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Head discomfort			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	1 / 2 (50.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Hypoaesthesia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sensory loss			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sinus headache			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Ear and labyrinth disorders			
Tinnitus			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Ocular hyperaemia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Visual acuity reduced			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal pain lower			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abnormal faeces			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			

subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eructation			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Faeces hard			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Paraesthesia oral			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dermatosis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Erythema			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pruritus generalised			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin odour abnormal			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin reaction			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Muscle tightness			

subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Neck pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vulvitis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 6 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Group B - MK-3682 150 mg (Cohort 4b)	Group B - MK-3682 50 mg (Cohort 3b)	Group B - MK-3682 25 mg (Cohort 2b)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 3 (66.67%)	1 / 3 (33.33%)	2 / 3 (66.67%)
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hot flush			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Chest discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	1	0	1
Feeling cold			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site anaesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site bruise			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site haematoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site reaction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			

Breast enlargement			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Menstruation delayed			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Claustrophobia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Investigations			
Amylase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Lipase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pancreatic enzymes increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Procedural nausea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dizziness postural			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Head discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1

Hypoaesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sensory loss			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sinus headache			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Tinnitus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Ocular hyperaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Visual acuity reduced			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			

Abdominal discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal pain lower			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abnormal faeces			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Diarrhoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Dyspepsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eructation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Faeces hard			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Gastritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Nausea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Paraesthesia oral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dermatosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Erythema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Pruritus generalised			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	1	0	0
Rash			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash papular			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin odour abnormal			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin reaction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Pollakiuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Muscle tightness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neck pain			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Pain in extremity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vulvitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Group B - MK-3682 300 mg (Cohort 5b)	Groups C and D - MK-3682 50 mg (capsule)	Groups C and D - MK-3682 150 mg (capsule)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 3 (66.67%)	8 / 11 (72.73%)	7 / 10 (70.00%)
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 3 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Chest discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 3 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Fatigue			
subjects affected / exposed	0 / 3 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0

Feeling cold			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site anaesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site bruise			
subjects affected / exposed	1 / 3 (33.33%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Vessel puncture site haematoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Vessel puncture site pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site reaction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Breast enlargement			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Menstruation delayed			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			

subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Rhinorrhoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Claustrophobia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Investigations			
Amylase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Lipase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pancreatic enzymes increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Procedural nausea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			

Atrial fibrillation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dizziness postural			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 3 (0.00%)	2 / 11 (18.18%)	0 / 10 (0.00%)
occurrences (all)	0	2	0
Head discomfort			
subjects affected / exposed	0 / 3 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Headache			
subjects affected / exposed	0 / 3 (0.00%)	2 / 11 (18.18%)	0 / 10 (0.00%)
occurrences (all)	0	2	0
Hypoaesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Sensory loss			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Sinus headache			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Tremor			

subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 11 (9.09%)	1 / 10 (10.00%)
occurrences (all)	0	1	1
Ear and labyrinth disorders			
Tinnitus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Ocular hyperaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Visual acuity reduced			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 3 (0.00%)	2 / 11 (18.18%)	0 / 10 (0.00%)
occurrences (all)	0	2	0
Abdominal pain lower			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Abnormal faeces			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Constipation			

subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Diarrhoea			
subjects affected / exposed	1 / 3 (33.33%)	2 / 11 (18.18%)	3 / 10 (30.00%)
occurrences (all)	1	2	3
Dry mouth			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Eructation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Faeces hard			
subjects affected / exposed	1 / 3 (33.33%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	1	0	0
Flatulence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Nausea			
subjects affected / exposed	0 / 3 (0.00%)	3 / 11 (27.27%)	0 / 10 (0.00%)
occurrences (all)	0	3	0
Paraesthesia oral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			

Dermatitis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Dermatosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Dry skin			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pruritus generalised			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Rash papular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Skin odour abnormal			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	1 / 10 (10.00%)
occurrences (all)	0	0	1
Skin reaction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			

subjects affected / exposed	0 / 3 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	0 / 3 (0.00%)	1 / 11 (9.09%)	2 / 10 (20.00%)
occurrences (all)	0	1	2
Muscle tightness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 11 (9.09%)	0 / 10 (0.00%)
occurrences (all)	0	1	0
Neck pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0
Vulvitis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 11 (0.00%)	0 / 10 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Group C - MK-3682 250 mg (capsule)	Groups C and D - MK-3682 300 mg (capsule)	Group C - MK-3682 400 mg (capsule)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 8 (87.50%)	8 / 18 (44.44%)	5 / 8 (62.50%)
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Chest discomfort			
subjects affected / exposed	0 / 8 (0.00%)	1 / 18 (5.56%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Chest pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	1 / 8 (12.50%)	1 / 18 (5.56%)	0 / 8 (0.00%)
occurrences (all)	1	1	0
Feeling cold			
subjects affected / exposed	0 / 8 (0.00%)	1 / 18 (5.56%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Pyrexia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Vessel puncture site anaesthesia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site bruise			
subjects affected / exposed	1 / 8 (12.50%)	1 / 18 (5.56%)	1 / 8 (12.50%)
occurrences (all)	1	2	1
Vessel puncture site haematoma			

subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site pain			
subjects affected / exposed	0 / 8 (0.00%)	1 / 18 (5.56%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Vessel puncture site reaction			
subjects affected / exposed	0 / 8 (0.00%)	1 / 18 (5.56%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Reproductive system and breast disorders			
Breast enlargement			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Menstruation delayed			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Epistaxis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Nasal congestion			
subjects affected / exposed	0 / 8 (0.00%)	1 / 18 (5.56%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Oropharyngeal pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Psychiatric disorders			
Claustrophobia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Insomnia			

subjects affected / exposed	0 / 8 (0.00%)	1 / 18 (5.56%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Investigations			
Amylase increased			
subjects affected / exposed	0 / 8 (0.00%)	1 / 18 (5.56%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 8 (0.00%)	1 / 18 (5.56%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Lipase increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pancreatic enzymes increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Procedural nausea			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 8 (0.00%)	1 / 18 (5.56%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Dizziness postural			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

Dysgeusia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Head discomfort			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	4 / 8 (50.00%)	2 / 18 (11.11%)	4 / 8 (50.00%)
occurrences (all)	4	4	5
Hypoaesthesia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 18 (5.56%)	1 / 8 (12.50%)
occurrences (all)	0	1	2
Sensory loss			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Sinus headache			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Somnolence			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	1 / 8 (12.50%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Ear and labyrinth disorders			
Tinnitus			
subjects affected / exposed	0 / 8 (0.00%)	1 / 18 (5.56%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Eye disorders			

Ocular hyperaemia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 18 (5.56%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Vision blurred			
subjects affected / exposed	0 / 8 (0.00%)	1 / 18 (5.56%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Visual acuity reduced			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Abdominal pain lower			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Abnormal faeces			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	1 / 8 (12.50%)	1 / 18 (5.56%)	1 / 8 (12.50%)
occurrences (all)	1	2	1
Diarrhoea			
subjects affected / exposed	3 / 8 (37.50%)	0 / 18 (0.00%)	2 / 8 (25.00%)
occurrences (all)	3	0	2
Dry mouth			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 18 (5.56%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Eructation			

subjects affected / exposed	0 / 8 (0.00%)	1 / 18 (5.56%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Faeces hard			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	1 / 8 (12.50%)	0 / 18 (0.00%)	2 / 8 (25.00%)
occurrences (all)	1	0	4
Paraesthesia oral			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Vomiting			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 18 (5.56%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Dermatosis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

Pruritus			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pruritus generalised			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Skin odour abnormal			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Skin reaction			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	1 / 8 (12.50%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Muscle tightness			
subjects affected / exposed	0 / 8 (0.00%)	1 / 18 (5.56%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal pain			

subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 18 (5.56%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Neck pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	1 / 8 (12.50%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	1 / 8 (12.50%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 8 (0.00%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vulvitis			
subjects affected / exposed	1 / 8 (12.50%)	0 / 18 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0

Non-serious adverse events	Group C - MK-3682 300 mg (tablet)	Groups C and D - Placebo (pooled)	Group C - MK-3682 450 mg (tablet)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	6 / 8 (75.00%)	6 / 9 (66.67%)	5 / 8 (62.50%)
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			

Chest discomfort			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	1 / 8 (12.50%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Feeling cold			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site anaesthesia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Vessel puncture site bruise			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site haematoma			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site reaction			
subjects affected / exposed	1 / 8 (12.50%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Reproductive system and breast disorders			
Breast enlargement			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Menstruation delayed			

subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Claustrophobia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Insomnia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Investigations			
Amylase increased			
subjects affected / exposed	0 / 8 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Lipase increased			
subjects affected / exposed	0 / 8 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Pancreatic enzymes increased			

subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Procedural nausea			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 8 (12.50%)	0 / 9 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Dizziness postural			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Head discomfort			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	3 / 8 (37.50%)	3 / 9 (33.33%)	0 / 8 (0.00%)
occurrences (all)	4	4	0
Hypoaesthesia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Sensory loss			

subjects affected / exposed	1 / 8 (12.50%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Sinus headache			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 8 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Tremor			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Neutropenia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 9 (11.11%)	1 / 8 (12.50%)
occurrences (all)	0	1	2
Ear and labyrinth disorders			
Tinnitus			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Ocular hyperaemia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Visual acuity reduced			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			

subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Abdominal pain lower			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Abnormal faeces			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Diarrhoea			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dry mouth			
subjects affected / exposed	0 / 8 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Dyspepsia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Eructation			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Faeces hard			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	1 / 8 (12.50%)	0 / 9 (0.00%)	2 / 8 (25.00%)
occurrences (all)	1	0	2
Paraesthesia oral			

subjects affected / exposed	1 / 8 (12.50%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Toothache			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dermatosis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 8 (0.00%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Pruritus			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pruritus generalised			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Skin odour abnormal			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

Skin reaction			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	1 / 8 (12.50%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Muscle tightness			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	1 / 8 (12.50%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	1 / 8 (12.50%)	1 / 9 (11.11%)	0 / 8 (0.00%)
occurrences (all)	1	1	0
Neck pain			
subjects affected / exposed	1 / 8 (12.50%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Pain in extremity			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			

Nasopharyngitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Upper respiratory tract infection			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Vulvitis			
subjects affected / exposed	0 / 8 (0.00%)	0 / 9 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Group E - MK-3682 150 mg (Cohort 1e)	Group E - MK-3682 450 mg (Cohort 3e)	Group E - MK-3682 300 mg (Cohort 2e)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 3 (0.00%)	5 / 8 (62.50%)	3 / 3 (100.00%)
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Chest discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Feeling cold			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Vessel puncture site anaesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site bruise			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site haematoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vessel puncture site reaction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Breast enlargement			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Menstruation delayed			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Nasal congestion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Claustrophobia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Investigations			
Amylase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Lipase increased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Pancreatic enzymes increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Procedural nausea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	1	0
Palpitations			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Dizziness postural			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Dysgeusia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Head discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	1 / 3 (33.33%)
occurrences (all)	0	1	1
Hypoaesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sensory loss			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Sinus headache			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Tremor			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neutropenia			

subjects affected / exposed	0 / 3 (0.00%)	1 / 8 (12.50%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Ear and labyrinth disorders			
Tinnitus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Ocular hyperaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Visual acuity reduced			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abdominal pain lower			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Abnormal faeces			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Diarrhoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dry mouth			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Eructation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Faeces hard			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Paraesthesia oral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Dermatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Dermatosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Dry skin			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Erythema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pruritus generalised			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	1
Skin odour abnormal			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Skin reaction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	1 / 3 (33.33%)
occurrences (all)	0	0	2
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Back pain			

subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Muscle tightness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	0 / 3 (0.00%)	2 / 8 (25.00%)	0 / 3 (0.00%)
occurrences (all)	0	2	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0
Vulvitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 8 (0.00%)	0 / 3 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Group F - MK-3682 300 mg (tablet)		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 8 (37.50%)		
Vascular disorders			

Flushing			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Hot flush			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
Chest discomfort			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Chest pain			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Fatigue			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Feeling cold			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Pyrexia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Vessel puncture site anaesthesia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Vessel puncture site bruise			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Vessel puncture site haematoma			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Vessel puncture site pain			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Vessel puncture site reaction			

subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0		
Reproductive system and breast disorders Breast enlargement subjects affected / exposed occurrences (all) Menstruation delayed subjects affected / exposed occurrences (all)	 0 / 8 (0.00%) 0 0 / 8 (0.00%) 0		
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all) Epistaxis subjects affected / exposed occurrences (all) Nasal congestion subjects affected / exposed occurrences (all) Oropharyngeal pain subjects affected / exposed occurrences (all) Rhinorrhoea subjects affected / exposed occurrences (all)	 0 / 8 (0.00%) 0 0 / 8 (0.00%) 0 0 / 8 (0.00%) 0 0 / 8 (0.00%) 0 0 / 8 (0.00%) 0		
Psychiatric disorders Claustrophobia subjects affected / exposed occurrences (all) Insomnia subjects affected / exposed occurrences (all)	 0 / 8 (0.00%) 0 0 / 8 (0.00%) 0		
Investigations Amylase increased subjects affected / exposed occurrences (all)	 0 / 8 (0.00%) 0		

Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Lipase increased			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Pancreatic enzymes increased			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Procedural nausea			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Palpitations			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Dizziness postural			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Dysgeusia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Head discomfort			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		

Headache			
subjects affected / exposed	3 / 8 (37.50%)		
occurrences (all)	3		
Hypoaesthesia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Sensory loss			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Sinus headache			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Somnolence			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Tremor			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Neutropenia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Ear and labyrinth disorders			
Tinnitus			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Eye disorders			
Ocular hyperaemia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Vision blurred			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Visual acuity reduced			

subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Abdominal pain			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Abdominal pain lower			
subjects affected / exposed	2 / 8 (25.00%)		
occurrences (all)	2		
Abnormal faeces			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Constipation			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Diarrhoea			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Dry mouth			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Dyspepsia			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Eructation			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Faeces hard			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Flatulence			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		

Gastritis				
subjects affected / exposed	0 / 8 (0.00%)			
occurrences (all)	0			
Nausea				
subjects affected / exposed	0 / 8 (0.00%)			
occurrences (all)	0			
Paraesthesia oral				
subjects affected / exposed	0 / 8 (0.00%)			
occurrences (all)	0			
Toothache				
subjects affected / exposed	0 / 8 (0.00%)			
occurrences (all)	0			
Vomiting				
subjects affected / exposed	0 / 8 (0.00%)			
occurrences (all)	0			
Skin and subcutaneous tissue disorders				
Dermatitis				
subjects affected / exposed	0 / 8 (0.00%)			
occurrences (all)	0			
Dermatosis				
subjects affected / exposed	0 / 8 (0.00%)			
occurrences (all)	0			
Dry skin				
subjects affected / exposed	0 / 8 (0.00%)			
occurrences (all)	0			
Erythema				
subjects affected / exposed	0 / 8 (0.00%)			
occurrences (all)	0			
Pruritus				
subjects affected / exposed	0 / 8 (0.00%)			
occurrences (all)	0			
Pruritus generalised				
subjects affected / exposed	0 / 8 (0.00%)			
occurrences (all)	0			
Rash				

subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Rash papular			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Skin odour abnormal			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Skin reaction			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Pollakiuria			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 8 (12.50%)		
occurrences (all)	1		
Back pain			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Muscle tightness			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Musculoskeletal pain			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Musculoskeletal stiffness			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Myalgia			

subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Neck pain			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Pain in extremity			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Upper respiratory tract infection			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		
Vulvitis			
subjects affected / exposed	0 / 8 (0.00%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

MK-3682 50 mg (Group D) and MK-3682 150 mg (Group D) Grade 3 abnormalities (neutropenia) were due to a lab processing error. MK-3682 450 mg (Group C) Grade 4 abnormality (neutropenia) was due to a lab processing error.

Notes: